{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Installing Necessary Libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: sentence_transformers in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (3.0.1)\n",
      "Requirement already satisfied: pypdf in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (4.2.0)\n",
      "Requirement already satisfied: faiss-cpu in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (1.8.0)\n",
      "Requirement already satisfied: transformers<5.0.0,>=4.34.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence_transformers) (4.41.2)\n",
      "Requirement already satisfied: tqdm in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence_transformers) (4.66.2)\n",
      "Requirement already satisfied: torch>=1.11.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence_transformers) (2.2.0)\n",
      "Requirement already satisfied: numpy in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence_transformers) (1.26.4)\n",
      "Requirement already satisfied: scikit-learn in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence_transformers) (1.4.0)\n",
      "Requirement already satisfied: scipy in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence_transformers) (1.12.0)\n",
      "Requirement already satisfied: huggingface-hub>=0.15.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence_transformers) (0.23.0)\n",
      "Requirement already satisfied: Pillow in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence_transformers) (10.2.0)\n",
      "Requirement already satisfied: typing_extensions>=4.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from pypdf) (4.9.0)\n",
      "Requirement already satisfied: filelock in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.15.1->sentence_transformers) (3.13.1)\n",
      "Requirement already satisfied: fsspec>=2023.5.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.15.1->sentence_transformers) (2024.2.0)\n",
      "Requirement already satisfied: packaging>=20.9 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.15.1->sentence_transformers) (23.2)\n",
      "Requirement already satisfied: pyyaml>=5.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.15.1->sentence_transformers) (6.0.1)\n",
      "Requirement already satisfied: requests in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.15.1->sentence_transformers) (2.31.0)\n",
      "Requirement already satisfied: sympy in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from torch>=1.11.0->sentence_transformers) (1.12)\n",
      "Requirement already satisfied: networkx in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from torch>=1.11.0->sentence_transformers) (3.2.1)\n",
      "Requirement already satisfied: jinja2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from torch>=1.11.0->sentence_transformers) (3.1.3)\n",
      "Requirement already satisfied: regex!=2019.12.17 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from transformers<5.0.0,>=4.34.0->sentence_transformers) (2023.12.25)\n",
      "Requirement already satisfied: tokenizers<0.20,>=0.19 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from transformers<5.0.0,>=4.34.0->sentence_transformers) (0.19.1)\n",
      "Requirement already satisfied: safetensors>=0.4.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from transformers<5.0.0,>=4.34.0->sentence_transformers) (0.4.2)\n",
      "Requirement already satisfied: joblib>=1.2.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from scikit-learn->sentence_transformers) (1.3.2)\n",
      "Requirement already satisfied: threadpoolctl>=2.0.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from scikit-learn->sentence_transformers) (3.2.0)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from jinja2->torch>=1.11.0->sentence_transformers) (2.1.3)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests->huggingface-hub>=0.15.1->sentence_transformers) (2.0.4)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests->huggingface-hub>=0.15.1->sentence_transformers) (3.4)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests->huggingface-hub>=0.15.1->sentence_transformers) (1.26.18)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests->huggingface-hub>=0.15.1->sentence_transformers) (2024.2.2)\n",
      "Requirement already satisfied: mpmath>=0.19 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sympy->torch>=1.11.0->sentence_transformers) (1.3.0)\n",
      "Requirement already satisfied: langchain in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (0.2.5)\n",
      "Requirement already satisfied: langchain-openai in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (0.1.8)\n",
      "Requirement already satisfied: PyYAML>=5.3 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (6.0.1)\n",
      "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (2.0.30)\n",
      "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (3.9.3)\n",
      "Requirement already satisfied: async-timeout<5.0.0,>=4.0.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (4.0.3)\n",
      "Requirement already satisfied: langchain-core<0.3.0,>=0.2.7 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (0.2.9)\n",
      "Requirement already satisfied: langchain-text-splitters<0.3.0,>=0.2.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (0.2.1)\n",
      "Requirement already satisfied: langsmith<0.2.0,>=0.1.17 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (0.1.81)\n",
      "Requirement already satisfied: numpy<2,>=1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (1.26.4)\n",
      "Requirement already satisfied: pydantic<3,>=1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (2.6.3)\n",
      "Requirement already satisfied: requests<3,>=2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (2.31.0)\n",
      "Requirement already satisfied: tenacity<9.0.0,>=8.1.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain) (8.2.3)\n",
      "Requirement already satisfied: openai<2.0.0,>=1.26.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-openai) (1.35.3)\n",
      "Requirement already satisfied: tiktoken<1,>=0.7 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-openai) (0.7.0)\n",
      "Requirement already satisfied: aiosignal>=1.1.2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.3.1)\n",
      "Requirement already satisfied: attrs>=17.3.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (23.1.0)\n",
      "Requirement already satisfied: frozenlist>=1.1.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.4.1)\n",
      "Requirement already satisfied: multidict<7.0,>=4.5 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (6.0.5)\n",
      "Requirement already satisfied: yarl<2.0,>=1.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.9.4)\n",
      "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-core<0.3.0,>=0.2.7->langchain) (1.33)\n",
      "Requirement already satisfied: packaging<25,>=23.2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-core<0.3.0,>=0.2.7->langchain) (23.2)\n",
      "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langsmith<0.2.0,>=0.1.17->langchain) (3.10.5)\n",
      "Requirement already satisfied: anyio<5,>=3.5.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from openai<2.0.0,>=1.26.0->langchain-openai) (4.2.0)\n",
      "Requirement already satisfied: distro<2,>=1.7.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from openai<2.0.0,>=1.26.0->langchain-openai) (1.9.0)\n",
      "Requirement already satisfied: httpx<1,>=0.23.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from openai<2.0.0,>=1.26.0->langchain-openai) (0.27.0)\n",
      "Requirement already satisfied: sniffio in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from openai<2.0.0,>=1.26.0->langchain-openai) (1.3.0)\n",
      "Requirement already satisfied: tqdm>4 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from openai<2.0.0,>=1.26.0->langchain-openai) (4.66.2)\n",
      "Requirement already satisfied: typing-extensions<5,>=4.7 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from openai<2.0.0,>=1.26.0->langchain-openai) (4.9.0)\n",
      "Requirement already satisfied: annotated-types>=0.4.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from pydantic<3,>=1->langchain) (0.6.0)\n",
      "Requirement already satisfied: pydantic-core==2.16.3 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from pydantic<3,>=1->langchain) (2.16.3)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests<3,>=2->langchain) (2.0.4)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests<3,>=2->langchain) (3.4)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests<3,>=2->langchain) (1.26.18)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests<3,>=2->langchain) (2024.2.2)\n",
      "Requirement already satisfied: regex>=2022.1.18 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from tiktoken<1,>=0.7->langchain-openai) (2023.12.25)\n",
      "Requirement already satisfied: exceptiongroup>=1.0.2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from anyio<5,>=3.5.0->openai<2.0.0,>=1.26.0->langchain-openai) (1.2.0)\n",
      "Requirement already satisfied: httpcore==1.* in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from httpx<1,>=0.23.0->openai<2.0.0,>=1.26.0->langchain-openai) (1.0.5)\n",
      "Requirement already satisfied: h11<0.15,>=0.13 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai<2.0.0,>=1.26.0->langchain-openai) (0.14.0)\n",
      "Requirement already satisfied: jsonpointer>=1.9 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.3.0,>=0.2.7->langchain) (3.0.0)\n",
      "Requirement already satisfied: langchain_community in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (0.2.5)\n",
      "Requirement already satisfied: PyYAML>=5.3 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (6.0.1)\n",
      "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (2.0.30)\n",
      "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (3.9.3)\n",
      "Requirement already satisfied: dataclasses-json<0.7,>=0.5.7 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (0.6.7)\n",
      "Requirement already satisfied: langchain<0.3.0,>=0.2.5 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (0.2.5)\n",
      "Requirement already satisfied: langchain-core<0.3.0,>=0.2.7 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (0.2.9)\n",
      "Requirement already satisfied: langsmith<0.2.0,>=0.1.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (0.1.81)\n",
      "Requirement already satisfied: numpy<2,>=1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (1.26.4)\n",
      "Requirement already satisfied: requests<3,>=2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (2.31.0)\n",
      "Requirement already satisfied: tenacity<9.0.0,>=8.1.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain_community) (8.2.3)\n",
      "Requirement already satisfied: aiosignal>=1.1.2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (1.3.1)\n",
      "Requirement already satisfied: attrs>=17.3.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (23.1.0)\n",
      "Requirement already satisfied: frozenlist>=1.1.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (1.4.1)\n",
      "Requirement already satisfied: multidict<7.0,>=4.5 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (6.0.5)\n",
      "Requirement already satisfied: yarl<2.0,>=1.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (1.9.4)\n",
      "Requirement already satisfied: async-timeout<5.0,>=4.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (4.0.3)\n",
      "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from dataclasses-json<0.7,>=0.5.7->langchain_community) (3.21.3)\n",
      "Requirement already satisfied: typing-inspect<1,>=0.4.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from dataclasses-json<0.7,>=0.5.7->langchain_community) (0.9.0)\n",
      "Requirement already satisfied: langchain-text-splitters<0.3.0,>=0.2.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain<0.3.0,>=0.2.5->langchain_community) (0.2.1)\n",
      "Requirement already satisfied: pydantic<3,>=1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain<0.3.0,>=0.2.5->langchain_community) (2.6.3)\n",
      "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-core<0.3.0,>=0.2.7->langchain_community) (1.33)\n",
      "Requirement already satisfied: packaging<25,>=23.2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-core<0.3.0,>=0.2.7->langchain_community) (23.2)\n",
      "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langsmith<0.2.0,>=0.1.0->langchain_community) (3.10.5)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests<3,>=2->langchain_community) (2.0.4)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests<3,>=2->langchain_community) (3.4)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests<3,>=2->langchain_community) (1.26.18)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests<3,>=2->langchain_community) (2024.2.2)\n",
      "Requirement already satisfied: typing-extensions>=4.6.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from SQLAlchemy<3,>=1.4->langchain_community) (4.9.0)\n",
      "Requirement already satisfied: jsonpointer>=1.9 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.3.0,>=0.2.7->langchain_community) (3.0.0)\n",
      "Requirement already satisfied: annotated-types>=0.4.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from pydantic<3,>=1->langchain<0.3.0,>=0.2.5->langchain_community) (0.6.0)\n",
      "Requirement already satisfied: pydantic-core==2.16.3 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from pydantic<3,>=1->langchain<0.3.0,>=0.2.5->langchain_community) (2.16.3)\n",
      "Requirement already satisfied: mypy-extensions>=0.3.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from typing-inspect<1,>=0.4.0->dataclasses-json<0.7,>=0.5.7->langchain_community) (1.0.0)\n",
      "Requirement already satisfied: langchain-huggingface in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (0.0.3)\n",
      "Requirement already satisfied: huggingface-hub>=0.23.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-huggingface) (0.23.0)\n",
      "Requirement already satisfied: langchain-core<0.3,>=0.1.52 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-huggingface) (0.2.9)\n",
      "Requirement already satisfied: sentence-transformers>=2.6.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-huggingface) (3.0.1)\n",
      "Requirement already satisfied: tokenizers>=0.19.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-huggingface) (0.19.1)\n",
      "Requirement already satisfied: transformers>=4.39.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-huggingface) (4.41.2)\n",
      "Requirement already satisfied: filelock in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (3.13.1)\n",
      "Requirement already satisfied: fsspec>=2023.5.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (2024.2.0)\n",
      "Requirement already satisfied: packaging>=20.9 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (23.2)\n",
      "Requirement already satisfied: pyyaml>=5.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (6.0.1)\n",
      "Requirement already satisfied: requests in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (2.31.0)\n",
      "Requirement already satisfied: tqdm>=4.42.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (4.66.2)\n",
      "Requirement already satisfied: typing-extensions>=3.7.4.3 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (4.9.0)\n",
      "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-core<0.3,>=0.1.52->langchain-huggingface) (1.33)\n",
      "Requirement already satisfied: langsmith<0.2.0,>=0.1.75 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-core<0.3,>=0.1.52->langchain-huggingface) (0.1.81)\n",
      "Requirement already satisfied: pydantic<3,>=1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-core<0.3,>=0.1.52->langchain-huggingface) (2.6.3)\n",
      "Requirement already satisfied: tenacity!=8.4.0,<9.0.0,>=8.1.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langchain-core<0.3,>=0.1.52->langchain-huggingface) (8.2.3)\n",
      "Requirement already satisfied: torch>=1.11.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (2.2.0)\n",
      "Requirement already satisfied: numpy in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (1.26.4)\n",
      "Requirement already satisfied: scikit-learn in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (1.4.0)\n",
      "Requirement already satisfied: scipy in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (1.12.0)\n",
      "Requirement already satisfied: Pillow in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (10.2.0)\n",
      "Requirement already satisfied: regex!=2019.12.17 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from transformers>=4.39.0->langchain-huggingface) (2023.12.25)\n",
      "Requirement already satisfied: safetensors>=0.4.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from transformers>=4.39.0->langchain-huggingface) (0.4.2)\n",
      "Requirement already satisfied: jsonpointer>=1.9 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.3,>=0.1.52->langchain-huggingface) (3.0.0)\n",
      "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from langsmith<0.2.0,>=0.1.75->langchain-core<0.3,>=0.1.52->langchain-huggingface) (3.10.5)\n",
      "Requirement already satisfied: annotated-types>=0.4.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from pydantic<3,>=1->langchain-core<0.3,>=0.1.52->langchain-huggingface) (0.6.0)\n",
      "Requirement already satisfied: pydantic-core==2.16.3 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from pydantic<3,>=1->langchain-core<0.3,>=0.1.52->langchain-huggingface) (2.16.3)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests->huggingface-hub>=0.23.0->langchain-huggingface) (2.0.4)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests->huggingface-hub>=0.23.0->langchain-huggingface) (3.4)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests->huggingface-hub>=0.23.0->langchain-huggingface) (1.26.18)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from requests->huggingface-hub>=0.23.0->langchain-huggingface) (2024.2.2)\n",
      "Requirement already satisfied: sympy in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (1.12)\n",
      "Requirement already satisfied: networkx in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (3.2.1)\n",
      "Requirement already satisfied: jinja2 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (3.1.3)\n",
      "Requirement already satisfied: joblib>=1.2.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from scikit-learn->sentence-transformers>=2.6.0->langchain-huggingface) (1.3.2)\n",
      "Requirement already satisfied: threadpoolctl>=2.0.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from scikit-learn->sentence-transformers>=2.6.0->langchain-huggingface) (3.2.0)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from jinja2->torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (2.1.3)\n",
      "Requirement already satisfied: mpmath>=0.19 in /Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages (from sympy->torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (1.3.0)\n"
     ]
    }
   ],
   "source": [
    "! pip install sentence_transformers pypdf faiss-cpu\n",
    "! pip install langchain langchain-openai\n",
    "! pip install langchain_community\n",
    "! pip install -U langchain-huggingface"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Importing necessary libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_huggingface import HuggingFaceEmbeddings\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.chains.combine_documents import create_stuff_documents_chain\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langchain.chains import create_retrieval_chain\n",
    "import dotenv"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Open AI Environment"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dotenv.load_dotenv()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages/langchain_core/_api/deprecation.py:139: LangChainDeprecationWarning: The class `ChatOpenAI` was deprecated in LangChain 0.0.10 and will be removed in 0.3.0. An updated version of the class exists in the langchain-openai package and should be used instead. To use it run `pip install -U langchain-openai` and import as `from langchain_openai import ChatOpenAI`.\n",
      "  warn_deprecated(\n"
     ]
    }
   ],
   "source": [
    "os.environ[\"OPENAI_API_KEY\"] = os.getenv(\"OPENAI_API_KEY\")\n",
    "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Importing Dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content=\"Title:  MeshAnything: Artist -Created Mesh Generation with Autoregressive Transformers  \\nAuthors:  buaacyw/meshanything  \\nDate:  14 Jun 2024  \\nDescription:  Recently, 3D assets created via reconstruction and generation have matched the \\nquality of manually crafted assets, highlighting their potential for replacement.  \\nStats:  417, 5.09 stars / hour  \\nCategories:  Decoder  \\nLinks:  Paper, Code  \\n \\nTitle:  Accessing GPT -4 level Mathematical Olympiad Solutions via Monte Carlo Tree Self -\\nrefine with LLaMa -3 8B  \\nAuthors:  trotsky1997/mathblackbox  \\nDate:  11 Jun 2024  \\nDescription:  This paper introduces the MCT Self -Refine algorithm, an innovative integration of \\nLarge Language Models (LLMs) with Monte Carlo Tree Search (MCTS), designed to enhance \\nperformance in complex mathematical reasoning tasks.  \\nStats:  279, 2.35 stars / hour  \\nCategories:  Decision Making, GSM8K +2  \\nLinks:  Paper, Code  \\n \\nTitle:  TextGrad: Automatic 'Differentiation' via Text  \\nAuthors:  zou-group/textgrad  \\nDate:  11 Jun 2024  \\nDescription:  Without modifying the framework, TextGrad improves the zero -shot accuracy of \\nGPT -4o in Google -Proof Question Answering, yields significant relative performance gain in \\noptimizing LeetCode -Hard coding problem solutions, improves prompts for reasoning, desi gns \\nnew druglike small molecules with desirable in silico binding, and designs radiation oncology \\ntreatment plans with high specificity.  \\nStats:  485, 2.04 stars / hour  \\nCategories:  Question Answering, Specificity  \\nLinks:  Paper, Code  \\n \\nTitle:  Scalable MatMul -free Language Modeling  \\nAuthors:  ridgerchu/matmulfreellm  \\nDate:  4 Jun 2024  \\nDescription:  Our experiments show that our proposed MatMul -free models achieve performance \\non-par with state -of-the-art Transformers that require far more memory during inference at a \\nscale up to at least 2.7B parameters.  \\nStats:  2,140, 1.98 stars / hour  \", metadata={'source': 'Dataset/RAG Input Doc.pdf', 'page': 0}),\n",
       " Document(page_content='Categories:  Language Modelling  \\nLinks:  Paper, Code  \\n \\nTitle:  VideoLLaMA 2: Advancing Spatial -Temporal Modeling and Audio Understanding in \\nVideo -LLMs  \\nAuthors:  damo -nlp-sg/videollama2  \\nDate:  11 Jun 2024  \\nDescription:  In this paper, we present the VideoLLaMA 2, a set of Video Large Language \\nModels (Video -LLMs) designed to enhance spatial -temporal modeling and audio understanding \\nin video and audio -oriented tasks.  \\nStats:  318, 1.50 stars / hour  \\nCategories:  Multiple -choice, Question Answering +3  \\nLinks:  Paper, Code  \\n ', metadata={'source': 'Dataset/RAG Input Doc.pdf', 'page': 1})]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "loader = PyPDFLoader(\"Dataset/RAG Input Doc.pdf\")\n",
    "documents = loader.load()\n",
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content=\"Title:  MeshAnything: Artist -Created Mesh Generation with Autoregressive Transformers  \\nAuthors:  buaacyw/meshanything  \\nDate:  14 Jun 2024  \\nDescription:  Recently, 3D assets created via reconstruction and generation have matched the \\nquality of manually crafted assets, highlighting their potential for replacement.  \\nStats:  417, 5.09 stars / hour  \\nCategories:  Decoder  \\nLinks:  Paper, Code  \\n \\nTitle:  Accessing GPT -4 level Mathematical Olympiad Solutions via Monte Carlo Tree Self -\\nrefine with LLaMa -3 8B  \\nAuthors:  trotsky1997/mathblackbox  \\nDate:  11 Jun 2024  \\nDescription:  This paper introduces the MCT Self -Refine algorithm, an innovative integration of \\nLarge Language Models (LLMs) with Monte Carlo Tree Search (MCTS), designed to enhance \\nperformance in complex mathematical reasoning tasks.  \\nStats:  279, 2.35 stars / hour  \\nCategories:  Decision Making, GSM8K +2  \\nLinks:  Paper, Code  \\n \\nTitle:  TextGrad: Automatic 'Differentiation' via Text  \\nAuthors:  zou-group/textgrad  \\nDate:  11 Jun 2024  \\nDescription:  Without modifying the framework, TextGrad improves the zero -shot accuracy of \\nGPT -4o in Google -Proof Question Answering, yields significant relative performance gain in \\noptimizing LeetCode -Hard coding problem solutions, improves prompts for reasoning, desi gns \\nnew druglike small molecules with desirable in silico binding, and designs radiation oncology \\ntreatment plans with high specificity.  \\nStats:  485, 2.04 stars / hour  \\nCategories:  Question Answering, Specificity  \\nLinks:  Paper, Code  \\n \\nTitle:  Scalable MatMul -free Language Modeling  \\nAuthors:  ridgerchu/matmulfreellm  \\nDate:  4 Jun 2024  \\nDescription:  Our experiments show that our proposed MatMul -free models achieve performance \\non-par with state -of-the-art Transformers that require far more memory during inference at a \\nscale up to at least 2.7B parameters.  \\nStats:  2,140, 1.98 stars / hour\", metadata={'source': 'Dataset/RAG Input Doc.pdf', 'page': 0}),\n",
       " Document(page_content='Categories:  Language Modelling  \\nLinks:  Paper, Code  \\n \\nTitle:  VideoLLaMA 2: Advancing Spatial -Temporal Modeling and Audio Understanding in \\nVideo -LLMs  \\nAuthors:  damo -nlp-sg/videollama2  \\nDate:  11 Jun 2024  \\nDescription:  In this paper, we present the VideoLLaMA 2, a set of Video Large Language \\nModels (Video -LLMs) designed to enhance spatial -temporal modeling and audio understanding \\nin video and audio -oriented tasks.  \\nStats:  318, 1.50 stars / hour  \\nCategories:  Multiple -choice, Question Answering +3  \\nLinks:  Paper, Code', metadata={'source': 'Dataset/RAG Input Doc.pdf', 'page': 1})]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Split text\n",
    "text = RecursiveCharacterTextSplitter().split_documents(documents)\n",
    "text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:11: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from tqdm.autonotebook import tqdm, trange\n",
      "/Users/taimourabdulkarim/miniconda3/envs/mlp/lib/python3.9/site-packages/huggingface_hub/file_download.py:1132: FutureWarning: `resume_download` is deprecated and will be removed in version 1.0.0. Downloads always resume when possible. If you want to force a new download, use `force_download=True`.\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "embeddings = HuggingFaceEmbeddings(\n",
    "    model_name=\"BAAI/bge-small-en-v1.5\", encode_kwargs={\"normalize_embeddings\": True}\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create a vectorstore\n",
    "vectorstore = FAISS.from_documents(text, embeddings)\n",
    "\n",
    "# Save the documents and embeddings\n",
    "vectorstore.save_local(\"vectorstore.db\")\n",
    "\n",
    "# create retriever\n",
    "retriever = vectorstore.as_retriever()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "# create document chain\n",
    "template = \"\"\"\"\n",
    "You are an assistant for question-answering tasks.\n",
    "Use the provided context only to answer the following question:\n",
    "\n",
    "<context>\n",
    "{context}\n",
    "</context>\n",
    "\n",
    "Question: {input}\n",
    "\"\"\"\n",
    "prompt = ChatPromptTemplate.from_template(template)\n",
    "doc_chain = create_stuff_documents_chain(llm, prompt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "chain = create_retrieval_chain(retriever, doc_chain)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question: What is the focus of the 'MeshAnything' project?\n",
      "Answer: The focus of the 'MeshAnything' project is artist-created mesh generation using autoregressive transformers.\n",
      "\n",
      "\n",
      "Question: Which paper discusses the integration of Large Language Models with Monte Carlo Tree Search?\n",
      "Answer: The paper titled \"Accessing GPT-4 level Mathematical Olympiad Solutions via Monte Carlo Tree Self-refine with LLaMa-3 8B\" discusses the integration of Large Language Models with Monte Carlo Tree Search.\n",
      "\n",
      "\n",
      "Question: What advancements does the 'VideoLLaMA 2' paper propose?\n",
      "Answer: The 'VideoLLaMA 2' paper proposes advancements in spatial-temporal modeling and audio understanding in video and audio-oriented tasks using Video Large Language Models (Video-LLMs).\n",
      "\n",
      "\n",
      "Question: Which paper was published most recently?\n",
      "Answer: The paper titled \"MeshAnything: Artist-Created Mesh Generation with Autoregressive Transformers\" was published most recently on 14 Jun 2024.\n",
      "\n",
      "\n",
      "Question: Identify a paper that deals with language modeling and its scalability.\n",
      "Answer: The paper titled \"Scalable MatMul -free Language Modeling\" deals with language modeling and its scalability.\n",
      "\n",
      "\n",
      "Question: Which paper aims at improving accuracy in Google-Proof Question Answering?\n",
      "Answer: The paper titled \"TextGrad: Automatic 'Differentiation' via Text\" aims at improving accuracy in Google-Proof Question Answering.\n",
      "\n",
      "\n",
      "Question: List the categories covered by the paper titled 'TextGrad: Automatic \"Differentiation\" via Text'.\n",
      "Answer: The categories covered by the paper titled 'TextGrad: Automatic \"Differentiation\" via Text' are Question Answering and Specificity.\n",
      "\n",
      "\n",
      "Question: Which paper received the highest number of stars per hour?\n",
      "Answer: The paper \"MeshAnything: Artist-Created Mesh Generation with Autoregressive Transformers\" received the highest number of stars per hour, with 5.09 stars / hour.\n",
      "\n",
      "\n",
      "Question: Who is Emma Stone?\n",
      "Answer: I'm sorry, but based on the provided context, there is no information about Emma Stone.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "questions = [\n",
    "    \"What is the focus of the 'MeshAnything' project?\",\n",
    "    \"Which paper discusses the integration of Large Language Models with Monte Carlo Tree Search?\",\n",
    "    \"What advancements does the 'VideoLLaMA 2' paper propose?\",\n",
    "    \"Which paper was published most recently?\",\n",
    "    \"Identify a paper that deals with language modeling and its scalability.\",\n",
    "    \"Which paper aims at improving accuracy in Google-Proof Question Answering?\",\n",
    "    \"List the categories covered by the paper titled 'TextGrad: Automatic \\\"Differentiation\\\" via Text'.\",\n",
    "    \"Which paper received the highest number of stars per hour?\",\n",
    "    \"Who is Emma Stone?\",  # irrelevant question\n",
    "]\n",
    "for question in questions:\n",
    "    response = chain.invoke({\"input\": question})\n",
    "    if response[\"answer\"]:\n",
    "        print(f\"Question: {question}\\nAnswer: {response['answer']}\\n\\n\")\n",
    "    else:\n",
    "        print(f\"Question: {question}\\nNo information\\n\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Trying with a Different Document"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='How Cancer ArisesHow cancer develops is no\\nlonger a mystery. During thepast two decades, investiga-\\ntors have made astonishing progress inidentifying the deepest bases of the pro-cess\\n—those at the molecular level. These\\ndiscoveries are robust: they will survivethe scrutiny of future generations of re-searchers, and they will form the foun-dation for revolutionary approaches totreatment. No one can predict exactlywhen therapies targeted to the molecu-lar alterations in cancer cells will ﬁndwide use, given that the translation ofnew understanding into clinical prac-tice is complicated, slow and expensive.But the effort is now under way.\\nIn truth, the term “cancer” refers to\\nmore than 100 forms of the disease. Al-most every tissue in the body can spawnmalignancies; some even yield severaltypes. What is more, each cancer hasunique features. Still, the basic processesthat produce these diverse tumors ap-pear to be quite similar. For that reason,\\nI will refer in this article to “cancer” ingeneric terms, drawing on one or anoth-er type to illustrate the rules that seemto apply universally.\\nThe 30 trillion cells of the normal,\\nhealthy body live in a complex, interde-pendent condominium, regulating oneanother’s proliferation. Indeed, normalcells reproduce only when instructed todo so by other cells in their vicinity. Suchunceasing collaboration ensures thateach tissue maintains a size and archi-tecture appropriate to the body’s needs. \\nCancer cells, in stark contrast, violate\\nthis scheme; they become deaf to theusual controls on proliferation and fol-low their own internal agenda for re-production. They also possess an evenmore insidious property\\n—the ability to\\nmigrate from the site where they began,invading nearby tissues and formingmasses at distant sites in the body. Tu-mors composed of such malignant cellsbecome more and more aggressive over\\ntime, and they become lethal when theydisrupt the tissues and organs needed forthe survival of the organism as a whole.\\nThis much is not new. But over the\\npast 20 years, scientists have uncovereda set of basic principles that govern thedevelopment of cancer. We now knowthat the cells in a tumor descend from acommon ancestral cell that at onepoint\\n—usually decades before a tumor\\nbecomes palpable —initiated a program\\nof inappropriate reproduction. Further,the malignant transformation of a cellcomes about through the accumulationof mutations in speciﬁc classes of thegenes within it. These genes provide thekey to understanding the processes atthe root of human cancer.\\nGenes are carried in the DNA mole-\\ncules of the chromosomes in the cell nu-cleus. A gene speciﬁes a sequence ofamino acids that must be linked togeth-er to make a particular protein; the pro-tein then carries out the work of thegene. When a gene is switched on, thecell responds by synthesizing the encod-ed protein. Mutations in a gene can per-turb a cell by changing the amounts orthe activities of the protein product.\\nTwo gene classes, which together con-\\nstitute only a small proportion of the fullgenetic set, play major roles in trigger-ing cancer. In their normal conﬁgura-tion, they choreograph the life cycle ofthe cell\\n—the intricate sequence of events\\nby which a cell enlarges and divides.Proto-oncogenes encourage such growth,whereas tumor suppressor genes inhibitit. \\nCollectively these two gene classes ac-\\n62 S cientific American September 1996How Cancer Arises\\nAn explosion of research is uncovering \\nthe long-hidden molecular underpinnings of cancer\\n—and suggesting new therapies\\nby Robert A. Weinberg\\n2  The altered cell and its descendants\\ncontinue to look normal, but they re-produce too much—a conditiontermed hyperplasia. After years, onein a million of these cells (\\npink) suf-\\nfers another mutation that furtherloosens controls on cell growth.3  In addition to proliferating excessively, the off-\\nspring of this cell appear abnormal in shape and inorientation; the tissue is now said to exhibit dys-plasia. Once again, after a time, a rare mutationthat alters cell behavior occurs (\\npurple ).The creation of a malignant tumor in epithelial tissue is depicted schemat-\\nically below. Epithelial cancers are the most common malignancies and\\nare called carcinomas. The mass seen here emerges as a result of mutationsin four genes, but the number of genes involved in real tumors can vary.Tumor Development \\nOccurs in StagesFundamental Understandings\\nHYPERPLASIAGENETICALLY ALTERED CELL\\nDYSPLASIADANA BURNS-PIZER1  Tumor development begins when\\nsome cell ( orange ) within a normal\\npopulation ( beige ) sustains a genet-\\nic mutation that increases itspropensity to proliferate when itwould normally rest.\\nCopyright 1996 Scientific American, Inc.\\n', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 0}),\n",
       " Document(page_content='count for much of the uncontr olled cell\\nproliferation seen in human cancers.\\nWhen mutated, pr oto-oncogenes can\\nbecome car cinogenic oncogenes that\\ndrive excessive multiplication. The mu -\\ntations may cause the pr oto-oncogene to\\nyield too much of its encoded gr owth-\\nstimulator y protein or an overly active\\nform of it. T umor suppr essor genes, in\\ncontrast, contribute to cancer when theyare inactivated by mutations. The r esult-\\ning loss of functional suppr essor pr o-\\nteins deprives the cell of cr ucial brakes\\nthat pr event inappr opriate gr owth.\\nFor a cancer ous tumor to develop,\\nmutations must occur in half a dozen ormore of the founding cell’ s growth-con -\\ntrolling genes. Alter ed for ms of yet oth -\\ner classes of genes may also par ticipate\\nin the cr eation of a malignancy , by spe -\\nciﬁcally enabling a pr oliferating cell to\\nbecome invasive or capable of spr ead-\\ning (metastasizing) thr oughout the body .\\nSignaling Systems Go A wry\\nVital clues to how mutated pr oto-\\noncogenes and tumor suppr essor\\ngenes contribute to cancer came fr om\\nstudying the r oles played within the cell\\nby the nor mal counterpar ts of these\\ngenes. After almost two decades of r e-\\nsearch, we now view the nor mal genet -\\nic functions with unpr ecedented clarity\\nand detail.\\nMany pr oto-oncogenes code for pr o-\\nteins in molecular “bucket brigades” thatrelay gr owth-stimulating signals fr om\\noutside the cell deep into its interior . The\\ngrowth of a cell becomes der egulatedwhen a mutation in one of its pr oto-on -\\ncogenes energizes a critical gr owth-stim -\\nulator y pathway , keeping it continu -\\nously active when it should be silent.\\nThese pathways within a cell r eceive\\nand pr ocess gr owth-stimulator y signals\\ntransmitted by other cells in a tissue.Such cell-to-cell signaling usually beginswhen one cell secr etes gr owth factors.\\nAfter r elease, these pr oteins move\\nthrough the spaces between cells and\\nbind to speciﬁc r eceptors\\n—antennalike\\nmolecules —on the sur face of other cells\\nnearby . Receptors span the outer mem -\\nbrane of the tar get cells, so that one end\\nprotrudes into the extracellular space,\\nand the other end pr ojects into the cell’ s\\ninterio r, its cytoplasm. When a gr owth-\\nstimulator y factor attaches to a r ecep-\\ntor, the r eceptor conveys a pr oliferative\\nsignal to pr oteins in the cytoplasm.\\nThese downstr eam pr oteins then emit\\nstimulator y signals to a succession of\\nother pr oteins, in a chain that ends in\\nthe hear t of the cell, its nucleus. W ithin\\nthe nucleus, pr oteins known as tran -\\nscription factors r espond by activating\\na cohor t of genes that help to usher the\\ncell thr ough its gr owth cycle.\\nSome oncogenes for ce cells to over -\\nproduce gr owth factors. Sar comas and\\ngliomas (cancers, r espectively , of con -\\nnective tissues and nonneur onal brain\\ncells) r elease excessive amounts of plate -\\nlet-derived gr owth factor . A number ofother cancer types secr ete too much\\ntransfor ming gr owth factor alpha. These\\nfactors act, as usual, on nearby cells,but, mor e impor tant, they may also\\nturn back and drive pr oliferation of the\\nsame cells that just pr oduced them. \\nResear chers have also identiﬁed on -\\ncogenic versions of r eceptor genes. The\\naberrant r eceptors speciﬁed by these on -\\ncogenes release a ﬂood of pr oliferative\\nsignals into the cell cytoplasm even whenno gr owth factors ar e present to ur ge\\nthe cell to r eplicate. For instance, br east\\ncancer cells often display Erb-B2 r ecep-\\ntor molecules that behave in this way . \\nStill other oncogenes in human tumors\\nperturb par ts of the signal cascade found\\nin the cytoplasm. The best understoodexample comes fr om the rasfamily of\\noncogenes. The pr oteins encoded by\\nnormal rasgenes transmit stimulator y\\nsignals fr om gr owth factor r eceptors to\\nother pr oteins far ther down the line.\\nThe pr oteins encoded by mutant ras\\ngenes, howeve r, ﬁre continuously , even\\nwhen gr owth factor r eceptors ar e not\\nprompting them. Hyperactive Ras pr o-\\nteins ar e found in about a quar ter of all\\nhuman tumors, including car cinomas\\nof the colon, pancr eas and lung. (Car ci-\\nnomas ar e by far the most common\\nforms of cancer; they originate in epi -\\nthelial cells, which line the body cavities\\n4  The af fected cells become still mor e\\nabnor mal in gr owth and appearance. If\\nthe tumor has not yet br oken thr ough\\nany boundaries between tissues, it iscalled in situ cancer . This tumor may\\nremain contained indefinitely; however ,\\nsome cells may eventually acquir e ad-\\nditional mutations (\\nblue).5  If the genetic changes allow the tu -\\nmor to begin invading underlying tis -\\nsue and to shed cells into the bloodor lymph, the mass is consider ed to\\nhave become malignant. The r ene-\\ngade cells ar e likely to establish new\\ntumors (metastases) thr oughout the\\nbody; these may become lethal bydisrupting a vital or gan.\\nHow Cancer ArisesIN SITU CANCERINVASIVE CANCER\\nBLOOD VESSEL\\nScientific American September 1996      63 Copyright 1996 Scientific American, Inc.\\n', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 1}),\n",
       " Document(page_content='and for m the outer layer of the skin.)\\nYet other oncogenes, such as those in\\nthe myc family , alter the activity of tran-\\nscription factors in the nucleus. Cellsnormally manufactur e Myc transcrip -\\ntion factors only after they have beenstimulated by gr owth factors impinging\\non the cell sur face. Once made, Myc\\nproteins activate genes that for ce cell\\ngrowth for ward. But in many types of\\ncancer , especially malignancies of the\\nblood-for ming tissues, Myc levels ar e\\nkept constantly high even in the ab -\\nsence of gr owth factors.\\nDiscover y of tr unk lines that car ry\\nproliferative messages fr om the cell sur -\\nface to its nucleus has been mor e than\\nintellectually satisfying. Because thesepathways ener gize the multiplication of\\nmalignant cells, they constitute attrac -\\ntive tar gets for scientists intent on de -\\nveloping new types of anticancer thera -peutics. In an exciting tur n of events, as\\nmany as half a dozen phar maceutical\\ncompanies ar e working on dr ugs de -\\nsigned to shut down aber rantly ﬁring\\ngrowth factor r eceptors. At least thr ee\\nother companies ar e attempting to devel -\\nop compounds that block the synthesisof aber rant Ras proteins. Both gr oups of\\nagents halt excessive signaling in cultur ed\\ncancer cells, but their utility in blockingthe gr owth of tumors in animals and\\nhumans r emains to be demonstrated.\\nTumor Suppr essors Stop W orking\\nTo become malignant, cells must do\\nmore than overstimulate their\\ngrowth-pr omoting machiner y. They\\nmust also devise ways to evade or ig -\\nnore braking signals issued by their nor -\\nmalneighbors in the tissue. Inhibitor y\\nmessages r eceived by a nor mal cell ﬂowto the nucleus much as stimulator y sig-\\nnals do —via molecular bucket brigades.\\nIn cancer cells, these inhibitor y brigades\\nmay be disr upted, ther eby enabling the\\ncell to ignor e normally potent inhibitor y\\nsignals at the sur face. Critical compo -\\nnents of these brigades, which ar e speci -\\nﬁed by tumor suppr essor genes, ar e ab-\\nsent or inactive in many types of cancercells.\\nA secr eted substance called transfor m-\\ning gr owth factor beta (TGF- ß) can stop\\nthe gr owth of various kinds of nor mal\\ncells. Some colon cancer cells becomeoblivious to TGF-ß by inactivating agene that encodes a sur face r eceptor for\\nthis substance. Some pancr eatic cancers\\ninactivate the DPC4 gene, whose pr o-\\ntein pr oduct may operate downstr eam\\nof the gr owth factor r eceptor . And a va -\\nriety of cancers discar d the p15gene,\\nwhich codes for a pr otein that, in r e-\\nHow Cancer Arises 64 Scientific American September 1996\\nCell cycle\\nclock decides\\nwhether cell\\nshould\\nproliferateCytoplasmic relay proteins\\nTranscription\\nfactors\\nProteins that\\ninhibit cell\\ndivisionNucleus\\nProteins\\nthat trigger\\ncell divisionDNAReceptors\\nat cell surfaceGrowth factor\\n(“go” signal)\\nNeighboring\\ncells releasegrowth-stimulatory factorsNeighboring\\ncells releasegrowth-inhibitoryfactors STIMULATORY\\nPATHWAYSINHIBITORY\\nPATHWAYS Normal cell\\nEXAMPLE OF \\nSTIMULATORY ABNORMALITYReceptor\\nfiresanyway\\nCell divides\\nin the absenceof stimulationby externalgrowth factorsNo growth\\nfactor attachesInhibitor\\n(“stop” signal)\\nEXAMPLE OF\\nINHIBITORYABNORMALITYReceptor\\nRelay\\nmoleculeis lost\\nSignaling\\nstops\\nCell divides\\nwhen itshould not,becauseinhibitorysignal failsto reach nucleusFund ament al Under standings\\nSIGNALING P ATHW AYS in nor mal cells convey gr owth-con -\\ntrolling messages fr om the outer sur face deep into the nucleus.\\nTher e a molecular apparatus known as the cell cycle clock col -\\nlects the messages and decides whether the cell should divide.Cancer cells often pr oliferate excessively because genetic muta -\\ntions cause stimulator y pathways (\\ngreen) to issue too many\\n“go” signals or because inhibitor y pathways ( red) can no longerconvey “stop” signals. A stimulator y pathway will become hy -\\nperactive if a mutation causes any component, such as a gr owth\\nfactor r eceptor ( box at left ), to issue stimulator y messages au -\\ntonomously , without waiting for commands fr om upstr eam.\\nConversely , inhibitor y pathways will shut down when some\\nconstituent, such as a cytoplasmic r elay (box at righ t), is elimi -\\nnated and thus br eaks the signaling chain.\\nDIMITR Y SCHIDLOVSKY\\nCopyright 1996 Scientific American, Inc.\\n', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 2}),\n",
       " Document(page_content='sponse to signals fr om TGF-ß, nor mally\\nshuts down the machiner y that guides\\nthe cell thr ough its gr owth cycle.\\nTumor suppr essor pr oteins can also\\nrestrain cell pr oliferation in other ways.\\nSome, for example, block the ﬂow ofsignals thr ough gr owth-stimulator y cir-\\ncuits. One such suppr essor is the pr od-\\nuct of the NF-1 gene. This cytoplasmic\\nmolecule ambushes the Ras protein be -\\nfore it can emit its gr owth-pr omoting\\ndirectives. Cells lacking NF-1, then, ar e\\nmissing an impor tant counterbalance\\nto Ras and to unchecked pr oliferation.\\nVarious studies have shown that the\\nintroduction of a tumor suppr essor gene\\ninto cancer cells that lack it can r estore\\na degr ee of nor malcy to the cells. This\\nresponse suggests a tantalizing way of\\ncombating cancer\\n—by pr oviding cancer\\ncells with intact versions of tumor sup-\\npressor genes they lost during tumor de -\\nvelopment. Although the concept is at -\\ntractive, this strategy is held back by thetechnical difﬁculties still encumberinggene therapy for many diseases. Cur rent\\nprocedur es fail to deliver genes to a lar ge\\nproportion of the cells in a tumor . Until\\nthis logistical obstacle is sur mounted,\\nthe use of gene therapy to cur e cancer\\nwill r emain a highly appealing but un -\\nfulﬁlled idea.\\nThe Clock Is Str uck\\nOver the past ﬁve years, impr essive\\nevidence has uncover ed the desti -\\nnation of stimulator y and inhibitor y\\npathways in the cell. They conver ge on\\na molecular apparatus in the cell nucle -\\nus that is often r eferred to as the cell cy -\\ncle clock. The clock is the executive de -\\ncision maker of the cell, and it appar -\\nently r uns amok in vir tually all types of\\nhuman cancer . In the nor mal cell, the\\nclock integrates the mixtur e of gr owth-\\nregulating signals r eceived by the cell\\nand decides whether the cell should passthrough its life cycle. If the answer is\\npositive, the clock leads the pr ocess. \\nThe cell cycle is composed of four\\nstages. In the G\\n1(gap 1) phase, the cell\\nincreases in size and pr epares to copy its\\nDNA. This copying occurs in the nextstage, ter med S (for synthesis), and en -\\nables the cell to duplicate pr ecisely its\\ncomplement of chr omosomes. After the\\nchromosomes ar e replicated, a second\\ngap period, ter med G\\n2, follows during\\nwhich the cell pr epares itself for M (mi -\\ntosis) —the time when the enlar ged par -\\nHow Cancer ArisesScientific American September 1996      65Some Genes Involved in Human Cancers\\nGenes known as pr oto-oncogenes code for pr oteins that stimulate cell division;\\nmutated for ms, called oncogenes, can cause the stimulator y proteins to be over -\\nactive, with the r esult that cells pr oliferate excessively . Tumor suppr essor genes code\\nfor pr oteins that inhibit cell division. Mutations can cause the pr oteins to be inacti -\\nvated and may thus deprive cells of needed r estraints on pr oliferation. Investigators\\nare still tr ying to decipher the specific functions of many tumor suppr essor genes. \\nONCOGENES\\nGenes for gr owth factors or their r eceptors\\nPDGF Codes for platelet-derived gr owth fa ctor. Involved in glioma \\n(a brain cancer)\\nerb-B Codes for the r eceptor for epider mal gr owth factor . Involved in \\nglioblastoma (a brain cance r) and br east cancer\\nerb-B2 Also called HER-2 or neu. Codes for a gr owth fa ctor receptor. Involved \\nin breast, salivar y gland and ovarian cancers\\nRET Codes for a gr owth factor r eceptor . Involved in thyr oid cancer\\nGenes for cytoplasmic r elays in stimulator y signaling pathways\\nKi-ras Involved in lung, ovarian, colon and pancr eatic cancers\\nN-ras Involved in leukemias\\nGenes for transcription factors that activate gr owth-pr omoting genes\\nc-myc Involved in leukemias and br east, stomach and lung cancers\\nN-myc Involved in neur oblastoma (a nerve cell cancer) and glioblastoma\\nL-myc Involved in lung cancer\\nGenes for other kinds of molecules\\nBcl-2 Codes for a pr otein that nor mally blocks cell suicide. Involved \\nin follicular B cell lymphoma\\nBcl-1 Also called PRAD1. Codes for cyclin D1, a stimulator y component of the \\ncell cycle clock. Involved in br east, head and neck cancers\\nMDM2 Codes for an antagonist of the p53 tumor suppr essor pr otein. Involved \\nin sar comas (connective tissue cancers) and other cancers\\nTUMOR SUPPRESSOR GENES\\nGenes for pr oteins in the cytoplasm\\nAPC Involved in colon and stomach cancers\\nDPC4 Codes for a r elay molecule in a signaling pathway that inhibits \\ncell division. Involved in pancr eatic cancer\\nNF-1 Codes for a pr otein that inhibits a stimulator y (Ras) pr otein. Involved \\nin neur ofibroma and pheo chromocytoma ( cancers of the peripheral \\nnervous system) and myeloid leu kemia\\nNF-2 Involved in meningioma and ependymoma (brain cancers) and \\nschwannoma (af fecting the wrapping ar ound peripheral ner ves)\\nGenes for pr oteins in the nucleus\\nMTS1 Codes for the p16 pr otein, a braking component of the cell cycle clock. \\nInvolved in a wide range of cancers\\nRB Codes for the pRB pr otein, a master brake of the cell cycle. Involved in \\nretinoblastoma and bone, bladder , small cell lung and br east cancer\\np53 Codes for the p53 pr otein, which can halt cell division and indu ce \\nabnor mal cells to kill themselves. Involved in a wide range of cancers\\nWT1 Involved in W ilms’ tumor of the kidney\\nGenes for pr oteins whose cellular location is not yet clear\\nBRCA1 Involved in br east and ovarian cancers\\nBRCA2 Involved in br east cancer\\nVHL Involved in r enal cell cancer\\nCopyright 1996 Scientific American, Inc.\\n', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 3}),\n",
       " Document(page_content='ent cell ﬁnally divides in half to pr oduce\\nits two daughters, each of which is en -\\ndowed with a complete set of chr omo-\\nsomes. The new daughter cells immedi -\\nately enter G1and may go thr ough the\\nfull cycle again. Alter natively , they may\\nstop cycling temporarily or per manently .\\nThe cell cycle clock pr ograms this\\nelaborate succession of events by meansof a variety of molecules. Its two essen -\\ntial components, cyclins and cyclin-de -\\npendent kinases (CDKs), associate withone another and initiate entrance intothe various stages of the cell cycle. InG\\n1, for instance, D-type cyclins bind to\\nCDKs 4 or 6, and the r esulting complex -\\nes act on a power ful gr owth-inhibitor y\\nmolecule —the pr otein known as pRB.This action r eleases the braking ef fect\\nof pRB and enables the cell to pr ogress\\ninto late G1and thence into S (DNA\\nsynthesis) phase [ see b in box below ].\\nVarious inhibitor y proteins can r e-\\nstrain for ward movement thr ough the\\ncycle. Among them ar e p15 (mentioned\\nearlier) and p16, both of which blockthe activity of the CDK par tners of cy -\\nHow Cancer Arises 66 Scientific American September 1996Fund ament al Under standings\\nG2MBeginning \\nof cycle Cell\\ndivides(mitosis)\\nCell rests\\nCell\\nreplicatesits DNACell enlarges\\nand makesnew proteinsCell prepares\\nto divide\\nRestriction point: cell\\ndecides whetherto commit itself tothe complete cycleSRG\\n1\\nG0Growth -\\ninhibitory\\nsignals\\nissued by\\nneighboring\\ncells\\nTransforming\\ngrowth\\nfactor beta\\n(an inhibitor)p27\\np15*Cyclin D–\\nCDK4/6 \\ncomplexGrowth-\\npromoting\\nsignals\\nissued by\\nneighboring\\ncells\\nCyclin D*\\nCyclin-\\ndependent\\nkinase 4* or 6\\n(CDK4/6)\\nEarly G1\\nPHASES OF CELL CYCLEInactive\\npRB \\nprotein\\n1 2 3\\nPhosphate\\nCyclin-\\ndependentkinaseActive\\ncomplexCyclin D or EATP\\nInactive pRBActive\\npRB(masterbrake)Inactive\\ntranscriptionfactor\\nActivetranscriptionfactor\\nGeneProteins\\nneeded for cell’s advancethrough itscycleMost, per haps all, human cancers gr ow inappr opriately not\\nonly because signaling pathways in cells ar e per turbed\\nbut also because the so-called cell cycle clock becomes deranged.The clock\\n—composed of an assembly of interacting pr oteins in\\nthe nucleus —normally integrates messages fr om the stimulator y\\nand inhibitor y pathways and, if the stimulator y messages win\\nout, pr ograms a cell’s advan ce through its cycle of gr owth and di -\\nvision. Pr ogression thr ough the four stages of the cell cycle (a) isdriven to a lar ge extent by rising levels of pr oteins called cyclins:\\nfirst the D type, follo wed by E, A and then B.\\nA crucial step in the cycle occurs late in G 1at the r estriction\\npoint (R), when the cell decides whether to commit itself to com -\\npleting the cycle. For the cell to pass thr ough R and enter S, a\\nmolecular “switch” must be flipped fr om “of f” to “on.” The switch\\nworks as follows (b): As levels of cyclin D and, later , cyclin E rise,\\nthese pr oteins combine with and activate enzymes called cyclin-\\ndependent kinases (1). The kinases (acting as par t of cyclin-ki -\\nnase complexes) grab phosphate gr oups (2) from molecules ofThe Cell Cycle Clock and CancerDIMITR Y SCHIDLOVSKYSTAGES OF THE CELL CYCLE\\nA MOLECULAR “SWITCH”THE CELL CYCLE CLOCK IN ACTIONa\\nbc\\nCopyright 1996 Scientific American, Inc.\\n', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 4}),\n",
       " Document(page_content='clin D, thus pr eventing the advance of\\nthe cell fr om G1into S. Another inhibi -\\ntor of CDKs, ter med p21, can act\\nthroughout the cell cycle. P21 is under\\ncontr ol of a tumor suppr essor pr otein,\\np53, that monitors the health of thecell, the integrity of its chr omosomal\\nDNA and the successful completion ofthe dif ferent steps in the cycle.Breast cancer cells often pr oduce ex -\\ncesses of cyclin D and cyclin E. In manycases of melanoma, skin cells have lostthe gene encoding the braking pr otein\\np16. Half of all types of human tumorslack a functional p53 pr otein. And in\\ncervical cancers trigger ed by infection\\nof cells with a human papillomavir us,\\nboth the pRB and p53 pr oteins ar e fre-quently disabled, eliminating two of the\\nclock’ s most vital r estraints. The end r e-\\nsult in all these cases is that the clockbegins to spin out of contr ol, ignoring\\nany exter nal war nings to stop. If investi -\\ngators can devise ways to impose clamps\\non the cyclins and CDKs active in thecell cycle, they may be able to halt can -\\ncer cells in their tracks.\\nHow Cancer Arises Scientific American September 1996      67DNA damage\\nor oxygen\\ndeprivation\\nCell\\ndivisionp53*\\nMDM2\\np21\\np16*Activity that promotes\\ncell division\\nMain path leading to\\ncell division\\nExternal signal that\\npromotes cell divisionActivity that discourages\\ncell division\\nExternal signal that\\ndiscourages cell divisionCyclin BCDC25ADNA \\nsynthesis\\nCyclin A–CDK1\\ncomplex\\nCyclin B–\\nCDK1 complexProteins\\ninvolved in DNA\\nsynthesisCyclin E–\\nCDK2 complex\\nLiberated\\ntranscription\\nfactorsCell suicide\\n(apoptosis)\\nCyclin E*\\nCDK2\\nCyclin A\\nCDK1\\nG2Late G1\\nRS Mgreen\\n*redPositive signal (increasing the amount\\nor activity of the target molecule)\\nNegative signal (decreasing the amount\\nor activity of the target molecule)\\nFeedback loopMutation or deregulation of gene for this\\nprotein has been found in human tumors  Active\\npRB protein*\\ncomplexed\\nwith inactive\\ntranscription\\nfactors\\n(master brake)ATP (adenosine triphosphate) and transfer them to a pr otein called\\npRB, the master brake of the cell cycle clock. When pRB lacksphosphates, it actively blocks cycling (and keeps the switch inthe “of f” position) by sequestering other pr oteins ter med tran -\\nscription factors. But after the cyclin-kinase complexes addenough phosphates to pRB, the brake stops working (\\n3; botto m);it releases the fa ctors, fr eeing them to act on genes ( 3; top ). The\\nliberated fa ctors then spur pr oduction of various pr oteins r equired\\nfor continued pr ogression thr ough the cell cycle.\\nIn figur e c below , the switch is pla ced in the lar ger conte xt of\\nthe many mole cular interactions that r egulate the cell cycle. Flip -\\nping of the switch to “on” can be seen above the R point. Overac -\\ntivity of the stimulator y proteins cyclin D, cyclin E and CDK4 have\\nbeen implicated in cer tain human cancers. Inactivation of various\\ninhibitor y proteins has also been documented. The af fected pr o-\\nteins include p53 (lost or inef fective in mor e than half of all tumor\\ntypes), pRB, p16 and p15. The net ef fect of any of these changes\\nis der egulation of the clock and, in tur n, excessive pr oliferation of\\nthe cell. —R.A.W .\\nCopyright 1996 Scientific American, Inc.\\n', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 5}),\n",
       " Document(page_content='I have so far discussed two ways that\\nour tissues nor mally hold down cell pr o-\\nliferation and avoid cancer . They pr e-\\nvent excess multiplication by deprivinga cell of gr owth-stimulator y factors or ,\\nconversely , by showering it with antipr o-\\nliferative factors. Still, as we have seen,cells on their way to becoming cancer ous\\noften cir cumvent these contr ols: they\\nstimulate themselves and tur n a deaf ear\\nto inhibitor y signals. Pr epared for such\\neventualities, the human body equipscells with cer tain backup systems that\\nguard against r unaway division. But\\nadditional mutations in the cell’ s genet -\\nic repertoire can over come even these\\ndefenses and contribute to cancer .\\nFail-Safe Systems Fail\\nOne such backup system, pr esent in\\neach human cell, pr ovokes the cell\\nto commit suicide (under go “apopto -\\nsis”) if some of its essential componentsare damaged or if its contr ol systems\\nare deregulated. For example, injur y to\\nchromosomal DNA can trigger apopto -\\nsis. Fur ther, recent work fr om a num -\\nber of laboratories indicates that cr ea-\\ntion of an oncogene or the disabling ofa tumor suppr essor gene within a cell\\ncan also induce this r esponse. Destr uc-\\ntion of a damaged cell is bad for the cellitself but makes sense for the body as awhole: the potential dangers posed to\\nthe or ganism by car cinogenic mutations\\nare far gr eater than the small price paid\\nin the loss of a single cell. The tumorsthat emer ge in our tissues, then, would\\nseem to arise fr om the rar e, genetically\\ndisturbed cell that somehow succeedsin evading the apoptotic pr ogram har d-\\nwired into its contr ol cir cuitry.\\nDeveloping cancer cells devise several\\nmeans of evading apoptosis. The p53\\nprotein, among its many functions, helps\\nto trigger cell suicide; its inactivation bymany tumor cells r educes the likelihood\\nthat genetically tr oubled cells will be\\neliminated. Cancer cells may also makeexcessive amounts of the pr otein Bcl-2,\\nwhich war ds off apoptosis efﬁciently .\\nRecently scientists have r ealized that\\nthis ability to escape apoptosis may en-\\ndanger patients not only by contributingto the expansion of a tumor but also bymaking the r esulting tumors r esistant to\\ntherapy . For years, it was assumed that\\nradiation therapy and many chemother -\\napeutic dr ugs killed malignant cells di -\\nrectly, by wr eaking widespr ead havoc\\nin their DNA. W e now know that the\\ntreatments often har m DNA to a r ela-\\ntively minor extent. Never theless, the\\naffected cells per ceive that the inﬂicted\\ndamage cannot be r epair ed easily , and\\nthey actively kill themselves. This dis -\\ncover y implies that cancer cells able toevade apoptosis will be far less r espon -\\nsive to tr eatment. By the same token, it\\nsuggests that therapies able to r estore a\\ncell’s capacity for suicide could combat\\ncancer by impr oving the ef fectiveness of\\nexisting radiation and chemotherapeu -\\ntic treatment strategies.\\nA second defense against r unaway\\nproliferation, quite distinct fr om the\\napoptotic program, is built into our cells\\nas well. This mechanism counts and lim -\\nits the total number of times cells canreproduce themselves.\\nCells Become Immor tal\\nMuch of what is known about this\\nsafeguar d has been lear ned fr om\\nstudies of cells cultur ed in a petri dish.\\nWhen cells ar e taken fr om a mouse or\\nhuman embr yo and gr own in cultur e,\\nthe population doubles ever y day or so.\\nBut after a pr edictable number of dou -\\nblings —50 to 60 in human cells —growth\\nstops, at which point the cells ar e said to\\nbe senescent. That, at least, is what hap -\\npens when cells have intact RBand p53\\ngenes. Cells that sustain inactivating mu -\\ntations in either of these genes continueto divide after their nor mal counterpar ts\\nenter senescence. Eventually , though, the\\nsurvivors r each a second stage, ter med\\ncrisis, in which they die in lar ge num -\\nbers. An occasional cell in this dyingpopulation, howeve r, will escape crisis\\nand become immor tal: it and its descen -\\ndants will multiply indeﬁnitely . \\nThese events imply the existence of a\\nmechanism that counts the number ofdoublings thr ough which a cell popula -\\ntion has passed. During the past severalyears, scientists have discover ed the mo -\\nlecular device that does this counting.\\nDNA segments at the ends of chr omo-\\nHow Cancer Arises 68 Scientific American September 1996Fund ament al Under standings\\nHUMAN CHROMOSOMES fr om a nor mal dividing cell ( top) occur as identical\\npairs; those number ed 8 to 18 ar e shown. Chr omosomes fr om a cer vical cancer cell, in\\ncontrast, display many abnor malities ( bottom ). Chr omosome 8, for instance, exhibits\\nthree disturbances: gain of copy number; deletion of genetic material fr om individual\\ncopies; and br eakage followed by joining of segments that do not belong together (far\\nright in 8). Copy loss, as in chr omosome 13, is also common. These various changes\\ncan favor tumor pr ogression if they activate an oncogene, incr ease the copies of an\\noncogene or eliminate a tumor suppr essor gene. The images wer e generated by spectral\\nkaryotyping, a new method for analyzing chr omosomes.MERR YN MACVILLE AND THOMAS REID National Center for Human Genome Research, NIH\\nNORMAL CELL\\n8\\n8q\\n8q9 10 11 12 13 14 15\\n8 9 10 13 14 15CANCER CELL\\nTruncated copies11 12\\nCopyright 1996 Scientific American, Inc.\\n', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 6}),\n",
       " Document(page_content='somes, known as telomer es, tally the\\nnumber of r eplicative generations\\nthrough which cell populations pass\\nand, at appropriate times, initiate senes -\\ncence and crisis. In so doing, they cir -\\ncumscribe the ability of cell populationsto expand indeﬁnitely [see “T elomer es,\\nTelomerase and Cancer ,” by Car ol W.\\nGreider and Elizabeth H. Blackbur n;\\nScientiﬁc American, February].\\nLike the plastic tips on shoelaces, the\\ntelomer e caps pr otect chr omosomal ends\\nfrom damage. In most human cells, telo -\\nmeres shorten a bit ever y time chr omo-\\nsomes ar e replicated during the S phase\\nof the cell cycle. Once the telomer es\\nshrink below some thr eshold length, they\\nsound an alar m that instr ucts cells to\\nenter senescence. If cells bypass senes -\\ncence, fur ther shrinkage of the telomer e\\nwill eventually trigger crisis: extr eme\\nshortening of the telomer es will cause\\nthe chr omosomes in a cell to fuse with\\none another or to br eak apar t, creating\\ngenetic chaos that is fatal to the cell.\\nIf the telomer e-based counting system\\noperated pr operly in cancer ous cells,\\ntheir excessive pr oliferation would be\\naborted long befor e tumors became ver y\\nlarge. Danger ous expansion would be\\nstemmed by the senescence pr ogram or ,\\nif the cell evaded that blockade, by dis -\\nruption of the chr omosomal ar ray at\\ncrisis. But this last defense is br eached\\nduring the development of most cancercells, over come by activation of a gene\\nthat codes for the enzyme telomerase.\\nThis enzyme, vir tually absent fr om\\nmost healthy cell types but pr esent in\\nalmost all tumor cells, systematically r e-\\nplaces telomeric segments that ar e usu -\\nally trimmed away during each cell cy -\\ncle. In so doing, it maintains the integri -\\nty of the telomer es and ther eby enablescells to r eplicate endlessly . The r esulting\\ncell immor tality can be tr oublesome in\\na couple of ways. Obviously , it allows\\ntumors to gr ow lar ge. It also gives pr e-\\ncancer ous or alr eady cancer ous cells\\ntime to accumulate additional mutationsthat will incr ease their ability to r epli-\\ncate, invade and ultimately metastasize.\\nFrom the point of view of a cancer\\ncell, pr oduction of a single enzyme is a\\nclever way to topple the mor tality bar -\\nrier. Yet dependence on one enzyme\\nmay r epresent an Achilles’ heel as well.\\nIf telomerase could be blocked in can -\\ncer cells, their telomer es would once\\nagain shrink whenever they divided,pushing these cells into crisis and death.For that r eason, a number of phar ma-\\nceutical ﬁr ms ar e attempting to develop\\ndrugs that tar get telomerase.\\nWhy Some Cancers Appear Early\\nIt normally takes decades for an incip -\\nient tumor to collect all the muta -\\ntions r equir ed for its malignant gr owth.\\nIn some individuals, howeve r, the time\\nfor tumor development is clearly com -\\npressed; they contract cer tain types of\\ncancer decades befor e the typical age of\\nonset of these cancers. How can tumorformation be accelerated?\\nIn many cases, this early onset is ex -\\nplained by the inheritance fr om one or\\nthe other par ent of a mutant cancer -\\ncausing gene. As a fer tilized egg begins\\nto divide and r eplicate, the set of genes\\nprovided by the sper m and egg is cop -\\nied and distributed to all the body’ s\\ncells. Now a typically rar e event\\n—a mu-\\ntation in a critical gr owth-contr olling\\ngene —becomes ubiquitous, because the\\nmutation is implanted in all the body’ s\\ncells, not mer ely in some randomly\\nstricken cell. In other wor ds, the pr ocess\\nof tumor for mation leapfr ogs over one\\nof its early , slowly occur ring steps, ac -\\ncelerating the pr ocess as a whole. As a\\nconsequence, tumor development, which\\nusually r equir es thr ee or four decades\\nto reach completion, may culminate in\\none or two. Because such mutant genescan pass fr om generation to generation,\\nmany members of a family may be atrisk for the early development of cancer .\\nAn inherited for m of colon cancer pr o-\\nvides a dramatic example. Most cases ofcolon cancer occur sporadically , the r e-\\nsults of random genetic events occur ring\\nduring a person’ s lifetime. In cer tain fam -\\nilies, however , many individuals ar e af-ﬂicted with early-onset colonic tumors,\\npreordained by an inherited gene. In the\\nsporadic cases, a rar e mutation silences\\na tumor suppr essor gene called APC in\\nan intestinal epithelial cell. The r esulting\\nproliferation of the mutant cell yields a\\nbenign polyp that may eventually pr o-\\ngress to a malignant car cinoma. But de -\\nfective for ms of APC may pass fr om\\nparents to childr en in cer tain families.\\nMembers of these families develop hun -\\ndreds, even thousands of colonic polyps\\nduring the ﬁrst decades of life, some ofwhich ar e likely to become transfor med\\ninto car cinomas.\\nThe list of familial cancer syndr omes\\nthat ar e now traceable dir ectly to inher -\\nitance of mutant tumor suppr essor genes\\nis growing. For instance, inherited defec -\\ntive versions of the gene for pRB often\\nlead to development of an eye cancer\\n—\\nretinoblastoma —in childr en; later in life\\nthe mutations account for a gr eatly in -\\ncreased risk of osteosar comas (bone can -\\ncers). Mutant inherited versions of thep53 tumor suppr essor gene yield tumors\\nat multiple sites, a condition known asthe Li-Fraumeni syndr ome (named in\\npart for Fr ederick Li, co-author of\\n“What Causes Cancer?”, page 80).And the r ecently isolated BRCA1 and\\nBRCA2 genes seem to account for the\\nbulk of familial br east cancers, encom -\\npassing as many as 20 per cent of all pr e-\\nmenopausal breast cancers in this coun -\\ntry and a substantial pr oportion of fa -\\nmilial ovarian cancers as well. \\nEarly onset of tumors is sometimes\\nexplained by inheritance of mutationsin another class of genes as well.   As Iimplied earlie r, most people avoid can -\\ncer until late in life or indeﬁnitely be -\\ncause they enter the world with pristinegenes. During the course of a lifetime,howeve r, our genes ar e attacked by car -\\ncinogens impor ted into our bodies fr om\\nthe envir onment and also by chemicals\\nproduced in our own cells. And genetic\\nerrors may be intr oduced when the en -\\nzymes that r eplicate DNA during cell\\ncycling make copying mistakes. For themost par t, such er rors ar e rapidly cor -\\nrected by a r epair system that operates\\nin ever y cell. Should the r epair system\\nslip up and fail to erase an er ror, the\\ndamage will become a per manent mu -\\ntation in one of the cell’ s genes and in\\nthat same gene in all descendant cells.\\nThe system’ s high r epair efﬁciency is\\none r eason many decades can pass be -\\nfore all the mutations needed for a ma -\\nHow Cancer Arises Scientific American September 1996      69\\n16 17 18\\n16 17 18\\nCopyright 1996 Scientific American, Inc.\\n', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 7}),\n",
       " Document(page_content='lignancy to develop will, by chance,\\ncome together within a single cell. Cer -\\ntain inherited defects, though, can ac -\\ncelerate tumor development thr ough a\\nparticularly insidious means: they im -\\npair the operation of pr oteins that r e-\\npair damaged DNA. As a r esult, muta -\\ntions that would nor mally accumulate\\nslowly will appear with alar ming fr e-\\nquency thr oughout the DNA of cells.\\nAmong the af fected genes ar e inevitably\\nthose contr olling cell pr oliferation. \\nSuch is the case in another inherited\\ncolon cancer , hereditar y nonpolyposis\\ncolon cancer . Afﬂicted individuals make\\ndefective versions of a pr otein r esponsi -\\nble for r epairing the copying mistakes\\nmade by the DNA r eplication appara -\\ntus. Because of this impair ment, colonic\\ncells cannot ﬁx DNA damage efﬁciently;they ther efore collect mutations rapidly ,\\naccelerating cancer development by twodecades or mor e. People af fected by an -\\nother familial cancer syndr ome, xer o-\\nderma pigmentosum, have inherited a\\ndefective copy of a gene that dir ects the\\nrepair of DNA damaged by ultraviolet\\nrays. These patients ar e prone to sever -\\nal types of sunlight-induced skin cancer .\\nSimilarly , cells of people bor n with a\\ndefective ATMgene have difﬁculty r ec-\\nognizing the pr esence of cer tain lesions\\nin the DNA and mobilizing the appr o-\\npriate r epair r esponse. These people ar e\\nsusceptible to neur ological degeneration,\\nblood vessel malfor mation and a variety\\nof tumors. Some r esear chers have pr o-\\nposed that as many as 10 per cent of in -\\nherited br east cancers may arise in pa -\\ntients with a defective copy of this gene.\\nOver the next decade, the list of can -\\ncer susceptibility genes will gr ow dra -\\nmatically , one of the fr uits of the Human\\nGenome Pr oject (which seeks to identify\\nevery gene in the human cell). T ogether\\nwith the incr easingly power ful tools of\\nDNA analysis, knowledge of these geneswill enable us to pr edict which members\\nof cancer -prone families ar e at high risk\\nand which have, thr ough good for tune,\\ninherited intact copies of these genes.\\nBeyond Pr oliferation\\nAlthough we have lear ned an enor -\\nmous amount about the genetic\\nbasis of r unaway cell pr oliferation, we\\nstill know rather little about the mutantgenes that contribute to later stages oftumor development, speciﬁcally thosethat allow tumor cells to attract bloodvessels for nourishment, to invade nearbytissues and to metastasize. But r esear ch\\nin these ar eas is moving rapidly . (Judah\\nFolkman describes the ingenuity of tu -\\nmor cells in generating their own bloodsupply in “Fighting  Cancer by Attack -\\ning Its Blood Supply ,” on page 150.\\nErkki Ruoslahti takes up metastasis in“How Cancer Spr eads” on page 72.)\\nWe are within striking distance of\\nwriting the detailed life histories of manyhuman tumors fr om star t to life-thr eat-\\nening ﬁnish. These biographies will bewritten in the language of genes andmolecules. W ithin a decade, we will\\nknow with extraor dinar y precision the\\nsuccession of events that constitute thecomplex evolution of nor mal cells into\\nhighly malignant, invasive derivatives. \\nBy then, we may come to understand\\nwhy cer tain localized masses never pr o-\\ngress beyond their benign, noninvasive\\nform to confr ont us with aggr essive ma -\\nlignancy. Such benign gr owths can be\\nfound in almost ever y organ of the body .\\nPerhaps we will also discer n why cer tain\\nmutant genes contribute to the for mation\\nof some types of cancer but not others.For example, mutant versions of the RB\\ntumor suppr essor gene appear often in\\nretinoblastoma, bladder car cinoma and\\nsmall cell lung car cinoma but ar e seen\\nonly occasionally in br east and colon car -cinomas. V ery likely , many of the solu -\\ntions to these mysteries will ﬂow fr om\\nresearch in developmental biology (em -\\nbryology). After all, the genes that gov -\\nern embr yonic development ar e, much\\nlater, the sour ces of our malignancies.\\nBy any measur e, the amount of infor -\\nmation gather ed over the past two de -\\ncades about the origins of cancer is with -\\nout parallel in the histor y of biomedical\\nresear ch. Some of this knowledge has\\nalready been put to good use, to build\\nmolecular tools for detecting and deter -\\nmining the aggr essiveness of cer tain types\\nof cance r, as David Sidransky discusses\\nin “Advances in Cancer Detection,” onpage 104. Still, despite so much insightinto cause, new curative therapies haveso far r emained elusive. One r eason is\\nthat tumor cells dif fer only minimally\\nfrom healthy ones; a minute fraction of\\nthe tens of thousands of genes in a cellsuffers damage during malignant trans-\\nformation. Thus, nor mal friend and\\nmalignant foe ar e woven of ver y similar\\ncloth, and any ﬁr e directed against the\\nenemy may do as much damage to nor -\\nmal tissue as to the intended tar get.\\nYet the course of the battle is chang -\\ning. The dif ferences between nor mal and\\ncancer cells may be subtle, but they ar e\\nreal. And the unique characteristics of\\ntumors pr ovide excellent tar gets for in -\\ntervention by newly developed dr ugs\\n[see the section “Therapies of the Fu -\\nture,” beginning on page 135]. The de -\\nvelopment of tar geted anticancer thera -\\npeutics is still in its infancy . This enter -\\nprise will soon move fr om hit-or -miss,\\nserendipitous discover yto rational de -\\nsign and accurate tar geting. I suspect\\nthat the ﬁrst decade of the new centur y\\nwill r eward us with cancer therapies\\nthat earlier generations could not havedreamed possible. Then this nation’ s\\nlong investment in basic cancer r esearch\\nwill begin to pay of f handsomely .\\nHow Cancer Arises 70 Scientific American September 1996The Aut hor\\nROBER T A. WEINBERG is Member of the Whitehead Insti -\\ntute for Biomedical Resear ch and a pr ofessor of biology at the\\nMassachusetts Institute of T echnology , wher e he ear ned his doc -\\ntoral degr ee in biology in 1969. His laborator y was instr umen -\\ntal in isolating the ﬁrst human oncogene and the ﬁrst human tu -\\nmor suppr essor gene. W einber g, a member of the National Acad -\\nemyof Sciences, has won many awar ds for his contributions to\\nthe understanding of cancer genetics, most r ecently the G.H.A.\\nClowes Memorial A ward of the American Association for Can -\\ncer Resear ch. This is his four th article for Scientiﬁc American.Further Reading\\nCancer: Science and Society . J. Cair ns. W . H. Fr eeman, 1978.\\nGenes and the Biology of C ancer. H. Varmus and R. A. W ein-\\nberg. Scientific American Librar y (distributed by W . H. Fr eeman),\\n1993.\\nThe Mul tistep N ature of C ancer. B. Vogelstein and K. W . Kinzler\\nin Trends in Genetics, Vol. 9, No. 4, pages 138–141; April 1993.\\nCancer: T he Rise of the Genetic P aradigm. J. M. Bishop in Genes\\nand Development, Vol. 9, No. 11, pages 1309–1315; June 1, 1995.\\nOncogenes. Second edition. G. M. Cooper . Jones and Bar tlett Pub -\\nlishers, Boston, 1995.Fund ament al Under standings\\nSA\\nCopyright 1996 Scientific American, Inc.\\n', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 8})]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "loader = PyPDFLoader(\"Dataset/Weinberg-tumor progression.pdf\")\n",
    "documents = loader.load()\n",
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='How Cancer ArisesHow cancer develops is no\\nlonger a mystery. During thepast two decades, investiga-\\ntors have made astonishing progress inidentifying the deepest bases of the pro-cess\\n—those at the molecular level. These\\ndiscoveries are robust: they will survivethe scrutiny of future generations of re-searchers, and they will form the foun-dation for revolutionary approaches totreatment. No one can predict exactlywhen therapies targeted to the molecu-lar alterations in cancer cells will ﬁndwide use, given that the translation ofnew understanding into clinical prac-tice is complicated, slow and expensive.But the effort is now under way.\\nIn truth, the term “cancer” refers to\\nmore than 100 forms of the disease. Al-most every tissue in the body can spawnmalignancies; some even yield severaltypes. What is more, each cancer hasunique features. Still, the basic processesthat produce these diverse tumors ap-pear to be quite similar. For that reason,\\nI will refer in this article to “cancer” ingeneric terms, drawing on one or anoth-er type to illustrate the rules that seemto apply universally.\\nThe 30 trillion cells of the normal,\\nhealthy body live in a complex, interde-pendent condominium, regulating oneanother’s proliferation. Indeed, normalcells reproduce only when instructed todo so by other cells in their vicinity. Suchunceasing collaboration ensures thateach tissue maintains a size and archi-tecture appropriate to the body’s needs. \\nCancer cells, in stark contrast, violate\\nthis scheme; they become deaf to theusual controls on proliferation and fol-low their own internal agenda for re-production. They also possess an evenmore insidious property\\n—the ability to\\nmigrate from the site where they began,invading nearby tissues and formingmasses at distant sites in the body. Tu-mors composed of such malignant cellsbecome more and more aggressive over\\ntime, and they become lethal when theydisrupt the tissues and organs needed forthe survival of the organism as a whole.\\nThis much is not new. But over the\\npast 20 years, scientists have uncovereda set of basic principles that govern thedevelopment of cancer. We now knowthat the cells in a tumor descend from acommon ancestral cell that at onepoint\\n—usually decades before a tumor\\nbecomes palpable —initiated a program\\nof inappropriate reproduction. Further,the malignant transformation of a cellcomes about through the accumulationof mutations in speciﬁc classes of thegenes within it. These genes provide thekey to understanding the processes atthe root of human cancer.\\nGenes are carried in the DNA mole-\\ncules of the chromosomes in the cell nu-cleus. A gene speciﬁes a sequence ofamino acids that must be linked togeth-er to make a particular protein; the pro-tein then carries out the work of thegene. When a gene is switched on, thecell responds by synthesizing the encod-ed protein. Mutations in a gene can per-turb a cell by changing the amounts orthe activities of the protein product.\\nTwo gene classes, which together con-\\nstitute only a small proportion of the fullgenetic set, play major roles in trigger-ing cancer. In their normal conﬁgura-tion, they choreograph the life cycle ofthe cell\\n—the intricate sequence of events\\nby which a cell enlarges and divides.Proto-oncogenes encourage such growth,whereas tumor suppressor genes inhibitit. \\nCollectively these two gene classes ac-\\n62 S cientific American September 1996How Cancer Arises\\nAn explosion of research is uncovering \\nthe long-hidden molecular underpinnings of cancer\\n—and suggesting new therapies\\nby Robert A. Weinberg\\n2  The altered cell and its descendants\\ncontinue to look normal, but they re-produce too much—a conditiontermed hyperplasia. After years, onein a million of these cells (\\npink) suf-\\nfers another mutation that furtherloosens controls on cell growth.3  In addition to proliferating excessively, the off-', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 0}),\n",
       " Document(page_content='pink) suf-\\nfers another mutation that furtherloosens controls on cell growth.3  In addition to proliferating excessively, the off-\\nspring of this cell appear abnormal in shape and inorientation; the tissue is now said to exhibit dys-plasia. Once again, after a time, a rare mutationthat alters cell behavior occurs (\\npurple ).The creation of a malignant tumor in epithelial tissue is depicted schemat-\\nically below. Epithelial cancers are the most common malignancies and\\nare called carcinomas. The mass seen here emerges as a result of mutationsin four genes, but the number of genes involved in real tumors can vary.Tumor Development \\nOccurs in StagesFundamental Understandings\\nHYPERPLASIAGENETICALLY ALTERED CELL\\nDYSPLASIADANA BURNS-PIZER1  Tumor development begins when\\nsome cell ( orange ) within a normal\\npopulation ( beige ) sustains a genet-\\nic mutation that increases itspropensity to proliferate when itwould normally rest.\\nCopyright 1996 Scientific American, Inc.', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 0}),\n",
       " Document(page_content='count for much of the uncontr olled cell\\nproliferation seen in human cancers.\\nWhen mutated, pr oto-oncogenes can\\nbecome car cinogenic oncogenes that\\ndrive excessive multiplication. The mu -\\ntations may cause the pr oto-oncogene to\\nyield too much of its encoded gr owth-\\nstimulator y protein or an overly active\\nform of it. T umor suppr essor genes, in\\ncontrast, contribute to cancer when theyare inactivated by mutations. The r esult-\\ning loss of functional suppr essor pr o-\\nteins deprives the cell of cr ucial brakes\\nthat pr event inappr opriate gr owth.\\nFor a cancer ous tumor to develop,\\nmutations must occur in half a dozen ormore of the founding cell’ s growth-con -\\ntrolling genes. Alter ed for ms of yet oth -\\ner classes of genes may also par ticipate\\nin the cr eation of a malignancy , by spe -\\nciﬁcally enabling a pr oliferating cell to\\nbecome invasive or capable of spr ead-\\ning (metastasizing) thr oughout the body .\\nSignaling Systems Go A wry\\nVital clues to how mutated pr oto-\\noncogenes and tumor suppr essor\\ngenes contribute to cancer came fr om\\nstudying the r oles played within the cell\\nby the nor mal counterpar ts of these\\ngenes. After almost two decades of r e-\\nsearch, we now view the nor mal genet -\\nic functions with unpr ecedented clarity\\nand detail.\\nMany pr oto-oncogenes code for pr o-\\nteins in molecular “bucket brigades” thatrelay gr owth-stimulating signals fr om\\noutside the cell deep into its interior . The\\ngrowth of a cell becomes der egulatedwhen a mutation in one of its pr oto-on -\\ncogenes energizes a critical gr owth-stim -\\nulator y pathway , keeping it continu -\\nously active when it should be silent.\\nThese pathways within a cell r eceive\\nand pr ocess gr owth-stimulator y signals\\ntransmitted by other cells in a tissue.Such cell-to-cell signaling usually beginswhen one cell secr etes gr owth factors.\\nAfter r elease, these pr oteins move\\nthrough the spaces between cells and\\nbind to speciﬁc r eceptors\\n—antennalike\\nmolecules —on the sur face of other cells\\nnearby . Receptors span the outer mem -\\nbrane of the tar get cells, so that one end\\nprotrudes into the extracellular space,\\nand the other end pr ojects into the cell’ s\\ninterio r, its cytoplasm. When a gr owth-\\nstimulator y factor attaches to a r ecep-\\ntor, the r eceptor conveys a pr oliferative\\nsignal to pr oteins in the cytoplasm.\\nThese downstr eam pr oteins then emit\\nstimulator y signals to a succession of\\nother pr oteins, in a chain that ends in\\nthe hear t of the cell, its nucleus. W ithin\\nthe nucleus, pr oteins known as tran -\\nscription factors r espond by activating\\na cohor t of genes that help to usher the\\ncell thr ough its gr owth cycle.\\nSome oncogenes for ce cells to over -\\nproduce gr owth factors. Sar comas and\\ngliomas (cancers, r espectively , of con -\\nnective tissues and nonneur onal brain\\ncells) r elease excessive amounts of plate -\\nlet-derived gr owth factor . A number ofother cancer types secr ete too much\\ntransfor ming gr owth factor alpha. These\\nfactors act, as usual, on nearby cells,but, mor e impor tant, they may also\\nturn back and drive pr oliferation of the\\nsame cells that just pr oduced them. \\nResear chers have also identiﬁed on -\\ncogenic versions of r eceptor genes. The\\naberrant r eceptors speciﬁed by these on -\\ncogenes release a ﬂood of pr oliferative\\nsignals into the cell cytoplasm even whenno gr owth factors ar e present to ur ge\\nthe cell to r eplicate. For instance, br east\\ncancer cells often display Erb-B2 r ecep-\\ntor molecules that behave in this way . \\nStill other oncogenes in human tumors\\nperturb par ts of the signal cascade found\\nin the cytoplasm. The best understoodexample comes fr om the rasfamily of\\noncogenes. The pr oteins encoded by\\nnormal rasgenes transmit stimulator y\\nsignals fr om gr owth factor r eceptors to\\nother pr oteins far ther down the line.\\nThe pr oteins encoded by mutant ras\\ngenes, howeve r, ﬁre continuously , even\\nwhen gr owth factor r eceptors ar e not\\nprompting them. Hyperactive Ras pr o-', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 1}),\n",
       " Document(page_content='other pr oteins far ther down the line.\\nThe pr oteins encoded by mutant ras\\ngenes, howeve r, ﬁre continuously , even\\nwhen gr owth factor r eceptors ar e not\\nprompting them. Hyperactive Ras pr o-\\nteins ar e found in about a quar ter of all\\nhuman tumors, including car cinomas\\nof the colon, pancr eas and lung. (Car ci-\\nnomas ar e by far the most common\\nforms of cancer; they originate in epi -\\nthelial cells, which line the body cavities\\n4  The af fected cells become still mor e\\nabnor mal in gr owth and appearance. If\\nthe tumor has not yet br oken thr ough\\nany boundaries between tissues, it iscalled in situ cancer . This tumor may\\nremain contained indefinitely; however ,\\nsome cells may eventually acquir e ad-\\nditional mutations (\\nblue).5  If the genetic changes allow the tu -\\nmor to begin invading underlying tis -\\nsue and to shed cells into the bloodor lymph, the mass is consider ed to\\nhave become malignant. The r ene-\\ngade cells ar e likely to establish new\\ntumors (metastases) thr oughout the\\nbody; these may become lethal bydisrupting a vital or gan.\\nHow Cancer ArisesIN SITU CANCERINVASIVE CANCER\\nBLOOD VESSEL\\nScientific American September 1996      63 Copyright 1996 Scientific American, Inc.', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 1}),\n",
       " Document(page_content='and for m the outer layer of the skin.)\\nYet other oncogenes, such as those in\\nthe myc family , alter the activity of tran-\\nscription factors in the nucleus. Cellsnormally manufactur e Myc transcrip -\\ntion factors only after they have beenstimulated by gr owth factors impinging\\non the cell sur face. Once made, Myc\\nproteins activate genes that for ce cell\\ngrowth for ward. But in many types of\\ncancer , especially malignancies of the\\nblood-for ming tissues, Myc levels ar e\\nkept constantly high even in the ab -\\nsence of gr owth factors.\\nDiscover y of tr unk lines that car ry\\nproliferative messages fr om the cell sur -\\nface to its nucleus has been mor e than\\nintellectually satisfying. Because thesepathways ener gize the multiplication of\\nmalignant cells, they constitute attrac -\\ntive tar gets for scientists intent on de -\\nveloping new types of anticancer thera -peutics. In an exciting tur n of events, as\\nmany as half a dozen phar maceutical\\ncompanies ar e working on dr ugs de -\\nsigned to shut down aber rantly ﬁring\\ngrowth factor r eceptors. At least thr ee\\nother companies ar e attempting to devel -\\nop compounds that block the synthesisof aber rant Ras proteins. Both gr oups of\\nagents halt excessive signaling in cultur ed\\ncancer cells, but their utility in blockingthe gr owth of tumors in animals and\\nhumans r emains to be demonstrated.\\nTumor Suppr essors Stop W orking\\nTo become malignant, cells must do\\nmore than overstimulate their\\ngrowth-pr omoting machiner y. They\\nmust also devise ways to evade or ig -\\nnore braking signals issued by their nor -\\nmalneighbors in the tissue. Inhibitor y\\nmessages r eceived by a nor mal cell ﬂowto the nucleus much as stimulator y sig-\\nnals do —via molecular bucket brigades.\\nIn cancer cells, these inhibitor y brigades\\nmay be disr upted, ther eby enabling the\\ncell to ignor e normally potent inhibitor y\\nsignals at the sur face. Critical compo -\\nnents of these brigades, which ar e speci -\\nﬁed by tumor suppr essor genes, ar e ab-\\nsent or inactive in many types of cancercells.\\nA secr eted substance called transfor m-\\ning gr owth factor beta (TGF- ß) can stop\\nthe gr owth of various kinds of nor mal\\ncells. Some colon cancer cells becomeoblivious to TGF-ß by inactivating agene that encodes a sur face r eceptor for\\nthis substance. Some pancr eatic cancers\\ninactivate the DPC4 gene, whose pr o-\\ntein pr oduct may operate downstr eam\\nof the gr owth factor r eceptor . And a va -\\nriety of cancers discar d the p15gene,\\nwhich codes for a pr otein that, in r e-\\nHow Cancer Arises 64 Scientific American September 1996\\nCell cycle\\nclock decides\\nwhether cell\\nshould\\nproliferateCytoplasmic relay proteins\\nTranscription\\nfactors\\nProteins that\\ninhibit cell\\ndivisionNucleus\\nProteins\\nthat trigger\\ncell divisionDNAReceptors\\nat cell surfaceGrowth factor\\n(“go” signal)\\nNeighboring\\ncells releasegrowth-stimulatory factorsNeighboring\\ncells releasegrowth-inhibitoryfactors STIMULATORY\\nPATHWAYSINHIBITORY\\nPATHWAYS Normal cell\\nEXAMPLE OF \\nSTIMULATORY ABNORMALITYReceptor\\nfiresanyway\\nCell divides\\nin the absenceof stimulationby externalgrowth factorsNo growth\\nfactor attachesInhibitor\\n(“stop” signal)\\nEXAMPLE OF\\nINHIBITORYABNORMALITYReceptor\\nRelay\\nmoleculeis lost\\nSignaling\\nstops\\nCell divides\\nwhen itshould not,becauseinhibitorysignal failsto reach nucleusFund ament al Under standings\\nSIGNALING P ATHW AYS in nor mal cells convey gr owth-con -\\ntrolling messages fr om the outer sur face deep into the nucleus.\\nTher e a molecular apparatus known as the cell cycle clock col -\\nlects the messages and decides whether the cell should divide.Cancer cells often pr oliferate excessively because genetic muta -\\ntions cause stimulator y pathways (\\ngreen) to issue too many\\n“go” signals or because inhibitor y pathways ( red) can no longerconvey “stop” signals. A stimulator y pathway will become hy -\\nperactive if a mutation causes any component, such as a gr owth\\nfactor r eceptor ( box at left ), to issue stimulator y messages au -', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 2}),\n",
       " Document(page_content='peractive if a mutation causes any component, such as a gr owth\\nfactor r eceptor ( box at left ), to issue stimulator y messages au -\\ntonomously , without waiting for commands fr om upstr eam.\\nConversely , inhibitor y pathways will shut down when some\\nconstituent, such as a cytoplasmic r elay (box at righ t), is elimi -\\nnated and thus br eaks the signaling chain.\\nDIMITR Y SCHIDLOVSKY\\nCopyright 1996 Scientific American, Inc.', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 2}),\n",
       " Document(page_content='sponse to signals fr om TGF-ß, nor mally\\nshuts down the machiner y that guides\\nthe cell thr ough its gr owth cycle.\\nTumor suppr essor pr oteins can also\\nrestrain cell pr oliferation in other ways.\\nSome, for example, block the ﬂow ofsignals thr ough gr owth-stimulator y cir-\\ncuits. One such suppr essor is the pr od-\\nuct of the NF-1 gene. This cytoplasmic\\nmolecule ambushes the Ras protein be -\\nfore it can emit its gr owth-pr omoting\\ndirectives. Cells lacking NF-1, then, ar e\\nmissing an impor tant counterbalance\\nto Ras and to unchecked pr oliferation.\\nVarious studies have shown that the\\nintroduction of a tumor suppr essor gene\\ninto cancer cells that lack it can r estore\\na degr ee of nor malcy to the cells. This\\nresponse suggests a tantalizing way of\\ncombating cancer\\n—by pr oviding cancer\\ncells with intact versions of tumor sup-\\npressor genes they lost during tumor de -\\nvelopment. Although the concept is at -\\ntractive, this strategy is held back by thetechnical difﬁculties still encumberinggene therapy for many diseases. Cur rent\\nprocedur es fail to deliver genes to a lar ge\\nproportion of the cells in a tumor . Until\\nthis logistical obstacle is sur mounted,\\nthe use of gene therapy to cur e cancer\\nwill r emain a highly appealing but un -\\nfulﬁlled idea.\\nThe Clock Is Str uck\\nOver the past ﬁve years, impr essive\\nevidence has uncover ed the desti -\\nnation of stimulator y and inhibitor y\\npathways in the cell. They conver ge on\\na molecular apparatus in the cell nucle -\\nus that is often r eferred to as the cell cy -\\ncle clock. The clock is the executive de -\\ncision maker of the cell, and it appar -\\nently r uns amok in vir tually all types of\\nhuman cancer . In the nor mal cell, the\\nclock integrates the mixtur e of gr owth-\\nregulating signals r eceived by the cell\\nand decides whether the cell should passthrough its life cycle. If the answer is\\npositive, the clock leads the pr ocess. \\nThe cell cycle is composed of four\\nstages. In the G\\n1(gap 1) phase, the cell\\nincreases in size and pr epares to copy its\\nDNA. This copying occurs in the nextstage, ter med S (for synthesis), and en -\\nables the cell to duplicate pr ecisely its\\ncomplement of chr omosomes. After the\\nchromosomes ar e replicated, a second\\ngap period, ter med G\\n2, follows during\\nwhich the cell pr epares itself for M (mi -\\ntosis) —the time when the enlar ged par -\\nHow Cancer ArisesScientific American September 1996      65Some Genes Involved in Human Cancers\\nGenes known as pr oto-oncogenes code for pr oteins that stimulate cell division;\\nmutated for ms, called oncogenes, can cause the stimulator y proteins to be over -\\nactive, with the r esult that cells pr oliferate excessively . Tumor suppr essor genes code\\nfor pr oteins that inhibit cell division. Mutations can cause the pr oteins to be inacti -\\nvated and may thus deprive cells of needed r estraints on pr oliferation. Investigators\\nare still tr ying to decipher the specific functions of many tumor suppr essor genes. \\nONCOGENES\\nGenes for gr owth factors or their r eceptors\\nPDGF Codes for platelet-derived gr owth fa ctor. Involved in glioma \\n(a brain cancer)\\nerb-B Codes for the r eceptor for epider mal gr owth factor . Involved in \\nglioblastoma (a brain cance r) and br east cancer\\nerb-B2 Also called HER-2 or neu. Codes for a gr owth fa ctor receptor. Involved \\nin breast, salivar y gland and ovarian cancers\\nRET Codes for a gr owth factor r eceptor . Involved in thyr oid cancer\\nGenes for cytoplasmic r elays in stimulator y signaling pathways\\nKi-ras Involved in lung, ovarian, colon and pancr eatic cancers\\nN-ras Involved in leukemias\\nGenes for transcription factors that activate gr owth-pr omoting genes\\nc-myc Involved in leukemias and br east, stomach and lung cancers\\nN-myc Involved in neur oblastoma (a nerve cell cancer) and glioblastoma\\nL-myc Involved in lung cancer\\nGenes for other kinds of molecules\\nBcl-2 Codes for a pr otein that nor mally blocks cell suicide. Involved \\nin follicular B cell lymphoma', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 3}),\n",
       " Document(page_content='L-myc Involved in lung cancer\\nGenes for other kinds of molecules\\nBcl-2 Codes for a pr otein that nor mally blocks cell suicide. Involved \\nin follicular B cell lymphoma\\nBcl-1 Also called PRAD1. Codes for cyclin D1, a stimulator y component of the \\ncell cycle clock. Involved in br east, head and neck cancers\\nMDM2 Codes for an antagonist of the p53 tumor suppr essor pr otein. Involved \\nin sar comas (connective tissue cancers) and other cancers\\nTUMOR SUPPRESSOR GENES\\nGenes for pr oteins in the cytoplasm\\nAPC Involved in colon and stomach cancers\\nDPC4 Codes for a r elay molecule in a signaling pathway that inhibits \\ncell division. Involved in pancr eatic cancer\\nNF-1 Codes for a pr otein that inhibits a stimulator y (Ras) pr otein. Involved \\nin neur ofibroma and pheo chromocytoma ( cancers of the peripheral \\nnervous system) and myeloid leu kemia\\nNF-2 Involved in meningioma and ependymoma (brain cancers) and \\nschwannoma (af fecting the wrapping ar ound peripheral ner ves)\\nGenes for pr oteins in the nucleus\\nMTS1 Codes for the p16 pr otein, a braking component of the cell cycle clock. \\nInvolved in a wide range of cancers\\nRB Codes for the pRB pr otein, a master brake of the cell cycle. Involved in \\nretinoblastoma and bone, bladder , small cell lung and br east cancer\\np53 Codes for the p53 pr otein, which can halt cell division and indu ce \\nabnor mal cells to kill themselves. Involved in a wide range of cancers\\nWT1 Involved in W ilms’ tumor of the kidney\\nGenes for pr oteins whose cellular location is not yet clear\\nBRCA1 Involved in br east and ovarian cancers\\nBRCA2 Involved in br east cancer\\nVHL Involved in r enal cell cancer\\nCopyright 1996 Scientific American, Inc.', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 3}),\n",
       " Document(page_content='ent cell ﬁnally divides in half to pr oduce\\nits two daughters, each of which is en -\\ndowed with a complete set of chr omo-\\nsomes. The new daughter cells immedi -\\nately enter G1and may go thr ough the\\nfull cycle again. Alter natively , they may\\nstop cycling temporarily or per manently .\\nThe cell cycle clock pr ograms this\\nelaborate succession of events by meansof a variety of molecules. Its two essen -\\ntial components, cyclins and cyclin-de -\\npendent kinases (CDKs), associate withone another and initiate entrance intothe various stages of the cell cycle. InG\\n1, for instance, D-type cyclins bind to\\nCDKs 4 or 6, and the r esulting complex -\\nes act on a power ful gr owth-inhibitor y\\nmolecule —the pr otein known as pRB.This action r eleases the braking ef fect\\nof pRB and enables the cell to pr ogress\\ninto late G1and thence into S (DNA\\nsynthesis) phase [ see b in box below ].\\nVarious inhibitor y proteins can r e-\\nstrain for ward movement thr ough the\\ncycle. Among them ar e p15 (mentioned\\nearlier) and p16, both of which blockthe activity of the CDK par tners of cy -\\nHow Cancer Arises 66 Scientific American September 1996Fund ament al Under standings\\nG2MBeginning \\nof cycle Cell\\ndivides(mitosis)\\nCell rests\\nCell\\nreplicatesits DNACell enlarges\\nand makesnew proteinsCell prepares\\nto divide\\nRestriction point: cell\\ndecides whetherto commit itself tothe complete cycleSRG\\n1\\nG0Growth -\\ninhibitory\\nsignals\\nissued by\\nneighboring\\ncells\\nTransforming\\ngrowth\\nfactor beta\\n(an inhibitor)p27\\np15*Cyclin D–\\nCDK4/6 \\ncomplexGrowth-\\npromoting\\nsignals\\nissued by\\nneighboring\\ncells\\nCyclin D*\\nCyclin-\\ndependent\\nkinase 4* or 6\\n(CDK4/6)\\nEarly G1\\nPHASES OF CELL CYCLEInactive\\npRB \\nprotein\\n1 2 3\\nPhosphate\\nCyclin-\\ndependentkinaseActive\\ncomplexCyclin D or EATP\\nInactive pRBActive\\npRB(masterbrake)Inactive\\ntranscriptionfactor\\nActivetranscriptionfactor\\nGeneProteins\\nneeded for cell’s advancethrough itscycleMost, per haps all, human cancers gr ow inappr opriately not\\nonly because signaling pathways in cells ar e per turbed\\nbut also because the so-called cell cycle clock becomes deranged.The clock\\n—composed of an assembly of interacting pr oteins in\\nthe nucleus —normally integrates messages fr om the stimulator y\\nand inhibitor y pathways and, if the stimulator y messages win\\nout, pr ograms a cell’s advan ce through its cycle of gr owth and di -\\nvision. Pr ogression thr ough the four stages of the cell cycle (a) isdriven to a lar ge extent by rising levels of pr oteins called cyclins:\\nfirst the D type, follo wed by E, A and then B.\\nA crucial step in the cycle occurs late in G 1at the r estriction\\npoint (R), when the cell decides whether to commit itself to com -\\npleting the cycle. For the cell to pass thr ough R and enter S, a\\nmolecular “switch” must be flipped fr om “of f” to “on.” The switch\\nworks as follows (b): As levels of cyclin D and, later , cyclin E rise,\\nthese pr oteins combine with and activate enzymes called cyclin-\\ndependent kinases (1). The kinases (acting as par t of cyclin-ki -\\nnase complexes) grab phosphate gr oups (2) from molecules ofThe Cell Cycle Clock and CancerDIMITR Y SCHIDLOVSKYSTAGES OF THE CELL CYCLE\\nA MOLECULAR “SWITCH”THE CELL CYCLE CLOCK IN ACTIONa\\nbc\\nCopyright 1996 Scientific American, Inc.', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 4}),\n",
       " Document(page_content='clin D, thus pr eventing the advance of\\nthe cell fr om G1into S. Another inhibi -\\ntor of CDKs, ter med p21, can act\\nthroughout the cell cycle. P21 is under\\ncontr ol of a tumor suppr essor pr otein,\\np53, that monitors the health of thecell, the integrity of its chr omosomal\\nDNA and the successful completion ofthe dif ferent steps in the cycle.Breast cancer cells often pr oduce ex -\\ncesses of cyclin D and cyclin E. In manycases of melanoma, skin cells have lostthe gene encoding the braking pr otein\\np16. Half of all types of human tumorslack a functional p53 pr otein. And in\\ncervical cancers trigger ed by infection\\nof cells with a human papillomavir us,\\nboth the pRB and p53 pr oteins ar e fre-quently disabled, eliminating two of the\\nclock’ s most vital r estraints. The end r e-\\nsult in all these cases is that the clockbegins to spin out of contr ol, ignoring\\nany exter nal war nings to stop. If investi -\\ngators can devise ways to impose clamps\\non the cyclins and CDKs active in thecell cycle, they may be able to halt can -\\ncer cells in their tracks.\\nHow Cancer Arises Scientific American September 1996      67DNA damage\\nor oxygen\\ndeprivation\\nCell\\ndivisionp53*\\nMDM2\\np21\\np16*Activity that promotes\\ncell division\\nMain path leading to\\ncell division\\nExternal signal that\\npromotes cell divisionActivity that discourages\\ncell division\\nExternal signal that\\ndiscourages cell divisionCyclin BCDC25ADNA \\nsynthesis\\nCyclin A–CDK1\\ncomplex\\nCyclin B–\\nCDK1 complexProteins\\ninvolved in DNA\\nsynthesisCyclin E–\\nCDK2 complex\\nLiberated\\ntranscription\\nfactorsCell suicide\\n(apoptosis)\\nCyclin E*\\nCDK2\\nCyclin A\\nCDK1\\nG2Late G1\\nRS Mgreen\\n*redPositive signal (increasing the amount\\nor activity of the target molecule)\\nNegative signal (decreasing the amount\\nor activity of the target molecule)\\nFeedback loopMutation or deregulation of gene for this\\nprotein has been found in human tumors  Active\\npRB protein*\\ncomplexed\\nwith inactive\\ntranscription\\nfactors\\n(master brake)ATP (adenosine triphosphate) and transfer them to a pr otein called\\npRB, the master brake of the cell cycle clock. When pRB lacksphosphates, it actively blocks cycling (and keeps the switch inthe “of f” position) by sequestering other pr oteins ter med tran -\\nscription factors. But after the cyclin-kinase complexes addenough phosphates to pRB, the brake stops working (\\n3; botto m);it releases the fa ctors, fr eeing them to act on genes ( 3; top ). The\\nliberated fa ctors then spur pr oduction of various pr oteins r equired\\nfor continued pr ogression thr ough the cell cycle.\\nIn figur e c below , the switch is pla ced in the lar ger conte xt of\\nthe many mole cular interactions that r egulate the cell cycle. Flip -\\nping of the switch to “on” can be seen above the R point. Overac -\\ntivity of the stimulator y proteins cyclin D, cyclin E and CDK4 have\\nbeen implicated in cer tain human cancers. Inactivation of various\\ninhibitor y proteins has also been documented. The af fected pr o-\\nteins include p53 (lost or inef fective in mor e than half of all tumor\\ntypes), pRB, p16 and p15. The net ef fect of any of these changes\\nis der egulation of the clock and, in tur n, excessive pr oliferation of\\nthe cell. —R.A.W .\\nCopyright 1996 Scientific American, Inc.', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 5}),\n",
       " Document(page_content='I have so far discussed two ways that\\nour tissues nor mally hold down cell pr o-\\nliferation and avoid cancer . They pr e-\\nvent excess multiplication by deprivinga cell of gr owth-stimulator y factors or ,\\nconversely , by showering it with antipr o-\\nliferative factors. Still, as we have seen,cells on their way to becoming cancer ous\\noften cir cumvent these contr ols: they\\nstimulate themselves and tur n a deaf ear\\nto inhibitor y signals. Pr epared for such\\neventualities, the human body equipscells with cer tain backup systems that\\nguard against r unaway division. But\\nadditional mutations in the cell’ s genet -\\nic repertoire can over come even these\\ndefenses and contribute to cancer .\\nFail-Safe Systems Fail\\nOne such backup system, pr esent in\\neach human cell, pr ovokes the cell\\nto commit suicide (under go “apopto -\\nsis”) if some of its essential componentsare damaged or if its contr ol systems\\nare deregulated. For example, injur y to\\nchromosomal DNA can trigger apopto -\\nsis. Fur ther, recent work fr om a num -\\nber of laboratories indicates that cr ea-\\ntion of an oncogene or the disabling ofa tumor suppr essor gene within a cell\\ncan also induce this r esponse. Destr uc-\\ntion of a damaged cell is bad for the cellitself but makes sense for the body as awhole: the potential dangers posed to\\nthe or ganism by car cinogenic mutations\\nare far gr eater than the small price paid\\nin the loss of a single cell. The tumorsthat emer ge in our tissues, then, would\\nseem to arise fr om the rar e, genetically\\ndisturbed cell that somehow succeedsin evading the apoptotic pr ogram har d-\\nwired into its contr ol cir cuitry.\\nDeveloping cancer cells devise several\\nmeans of evading apoptosis. The p53\\nprotein, among its many functions, helps\\nto trigger cell suicide; its inactivation bymany tumor cells r educes the likelihood\\nthat genetically tr oubled cells will be\\neliminated. Cancer cells may also makeexcessive amounts of the pr otein Bcl-2,\\nwhich war ds off apoptosis efﬁciently .\\nRecently scientists have r ealized that\\nthis ability to escape apoptosis may en-\\ndanger patients not only by contributingto the expansion of a tumor but also bymaking the r esulting tumors r esistant to\\ntherapy . For years, it was assumed that\\nradiation therapy and many chemother -\\napeutic dr ugs killed malignant cells di -\\nrectly, by wr eaking widespr ead havoc\\nin their DNA. W e now know that the\\ntreatments often har m DNA to a r ela-\\ntively minor extent. Never theless, the\\naffected cells per ceive that the inﬂicted\\ndamage cannot be r epair ed easily , and\\nthey actively kill themselves. This dis -\\ncover y implies that cancer cells able toevade apoptosis will be far less r espon -\\nsive to tr eatment. By the same token, it\\nsuggests that therapies able to r estore a\\ncell’s capacity for suicide could combat\\ncancer by impr oving the ef fectiveness of\\nexisting radiation and chemotherapeu -\\ntic treatment strategies.\\nA second defense against r unaway\\nproliferation, quite distinct fr om the\\napoptotic program, is built into our cells\\nas well. This mechanism counts and lim -\\nits the total number of times cells canreproduce themselves.\\nCells Become Immor tal\\nMuch of what is known about this\\nsafeguar d has been lear ned fr om\\nstudies of cells cultur ed in a petri dish.\\nWhen cells ar e taken fr om a mouse or\\nhuman embr yo and gr own in cultur e,\\nthe population doubles ever y day or so.\\nBut after a pr edictable number of dou -\\nblings —50 to 60 in human cells —growth\\nstops, at which point the cells ar e said to\\nbe senescent. That, at least, is what hap -\\npens when cells have intact RBand p53\\ngenes. Cells that sustain inactivating mu -\\ntations in either of these genes continueto divide after their nor mal counterpar ts\\nenter senescence. Eventually , though, the\\nsurvivors r each a second stage, ter med\\ncrisis, in which they die in lar ge num -\\nbers. An occasional cell in this dyingpopulation, howeve r, will escape crisis\\nand become immor tal: it and its descen -', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 6}),\n",
       " Document(page_content='crisis, in which they die in lar ge num -\\nbers. An occasional cell in this dyingpopulation, howeve r, will escape crisis\\nand become immor tal: it and its descen -\\ndants will multiply indeﬁnitely . \\nThese events imply the existence of a\\nmechanism that counts the number ofdoublings thr ough which a cell popula -\\ntion has passed. During the past severalyears, scientists have discover ed the mo -\\nlecular device that does this counting.\\nDNA segments at the ends of chr omo-\\nHow Cancer Arises 68 Scientific American September 1996Fund ament al Under standings\\nHUMAN CHROMOSOMES fr om a nor mal dividing cell ( top) occur as identical\\npairs; those number ed 8 to 18 ar e shown. Chr omosomes fr om a cer vical cancer cell, in\\ncontrast, display many abnor malities ( bottom ). Chr omosome 8, for instance, exhibits\\nthree disturbances: gain of copy number; deletion of genetic material fr om individual\\ncopies; and br eakage followed by joining of segments that do not belong together (far\\nright in 8). Copy loss, as in chr omosome 13, is also common. These various changes\\ncan favor tumor pr ogression if they activate an oncogene, incr ease the copies of an\\noncogene or eliminate a tumor suppr essor gene. The images wer e generated by spectral\\nkaryotyping, a new method for analyzing chr omosomes.MERR YN MACVILLE AND THOMAS REID National Center for Human Genome Research, NIH\\nNORMAL CELL\\n8\\n8q\\n8q9 10 11 12 13 14 15\\n8 9 10 13 14 15CANCER CELL\\nTruncated copies11 12\\nCopyright 1996 Scientific American, Inc.', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 6}),\n",
       " Document(page_content='somes, known as telomer es, tally the\\nnumber of r eplicative generations\\nthrough which cell populations pass\\nand, at appropriate times, initiate senes -\\ncence and crisis. In so doing, they cir -\\ncumscribe the ability of cell populationsto expand indeﬁnitely [see “T elomer es,\\nTelomerase and Cancer ,” by Car ol W.\\nGreider and Elizabeth H. Blackbur n;\\nScientiﬁc American, February].\\nLike the plastic tips on shoelaces, the\\ntelomer e caps pr otect chr omosomal ends\\nfrom damage. In most human cells, telo -\\nmeres shorten a bit ever y time chr omo-\\nsomes ar e replicated during the S phase\\nof the cell cycle. Once the telomer es\\nshrink below some thr eshold length, they\\nsound an alar m that instr ucts cells to\\nenter senescence. If cells bypass senes -\\ncence, fur ther shrinkage of the telomer e\\nwill eventually trigger crisis: extr eme\\nshortening of the telomer es will cause\\nthe chr omosomes in a cell to fuse with\\none another or to br eak apar t, creating\\ngenetic chaos that is fatal to the cell.\\nIf the telomer e-based counting system\\noperated pr operly in cancer ous cells,\\ntheir excessive pr oliferation would be\\naborted long befor e tumors became ver y\\nlarge. Danger ous expansion would be\\nstemmed by the senescence pr ogram or ,\\nif the cell evaded that blockade, by dis -\\nruption of the chr omosomal ar ray at\\ncrisis. But this last defense is br eached\\nduring the development of most cancercells, over come by activation of a gene\\nthat codes for the enzyme telomerase.\\nThis enzyme, vir tually absent fr om\\nmost healthy cell types but pr esent in\\nalmost all tumor cells, systematically r e-\\nplaces telomeric segments that ar e usu -\\nally trimmed away during each cell cy -\\ncle. In so doing, it maintains the integri -\\nty of the telomer es and ther eby enablescells to r eplicate endlessly . The r esulting\\ncell immor tality can be tr oublesome in\\na couple of ways. Obviously , it allows\\ntumors to gr ow lar ge. It also gives pr e-\\ncancer ous or alr eady cancer ous cells\\ntime to accumulate additional mutationsthat will incr ease their ability to r epli-\\ncate, invade and ultimately metastasize.\\nFrom the point of view of a cancer\\ncell, pr oduction of a single enzyme is a\\nclever way to topple the mor tality bar -\\nrier. Yet dependence on one enzyme\\nmay r epresent an Achilles’ heel as well.\\nIf telomerase could be blocked in can -\\ncer cells, their telomer es would once\\nagain shrink whenever they divided,pushing these cells into crisis and death.For that r eason, a number of phar ma-\\nceutical ﬁr ms ar e attempting to develop\\ndrugs that tar get telomerase.\\nWhy Some Cancers Appear Early\\nIt normally takes decades for an incip -\\nient tumor to collect all the muta -\\ntions r equir ed for its malignant gr owth.\\nIn some individuals, howeve r, the time\\nfor tumor development is clearly com -\\npressed; they contract cer tain types of\\ncancer decades befor e the typical age of\\nonset of these cancers. How can tumorformation be accelerated?\\nIn many cases, this early onset is ex -\\nplained by the inheritance fr om one or\\nthe other par ent of a mutant cancer -\\ncausing gene. As a fer tilized egg begins\\nto divide and r eplicate, the set of genes\\nprovided by the sper m and egg is cop -\\nied and distributed to all the body’ s\\ncells. Now a typically rar e event\\n—a mu-\\ntation in a critical gr owth-contr olling\\ngene —becomes ubiquitous, because the\\nmutation is implanted in all the body’ s\\ncells, not mer ely in some randomly\\nstricken cell. In other wor ds, the pr ocess\\nof tumor for mation leapfr ogs over one\\nof its early , slowly occur ring steps, ac -\\ncelerating the pr ocess as a whole. As a\\nconsequence, tumor development, which\\nusually r equir es thr ee or four decades\\nto reach completion, may culminate in\\none or two. Because such mutant genescan pass fr om generation to generation,\\nmany members of a family may be atrisk for the early development of cancer .\\nAn inherited for m of colon cancer pr o-\\nvides a dramatic example. Most cases ofcolon cancer occur sporadically , the r e-', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 7}),\n",
       " Document(page_content='many members of a family may be atrisk for the early development of cancer .\\nAn inherited for m of colon cancer pr o-\\nvides a dramatic example. Most cases ofcolon cancer occur sporadically , the r e-\\nsults of random genetic events occur ring\\nduring a person’ s lifetime. In cer tain fam -\\nilies, however , many individuals ar e af-ﬂicted with early-onset colonic tumors,\\npreordained by an inherited gene. In the\\nsporadic cases, a rar e mutation silences\\na tumor suppr essor gene called APC in\\nan intestinal epithelial cell. The r esulting\\nproliferation of the mutant cell yields a\\nbenign polyp that may eventually pr o-\\ngress to a malignant car cinoma. But de -\\nfective for ms of APC may pass fr om\\nparents to childr en in cer tain families.\\nMembers of these families develop hun -\\ndreds, even thousands of colonic polyps\\nduring the ﬁrst decades of life, some ofwhich ar e likely to become transfor med\\ninto car cinomas.\\nThe list of familial cancer syndr omes\\nthat ar e now traceable dir ectly to inher -\\nitance of mutant tumor suppr essor genes\\nis growing. For instance, inherited defec -\\ntive versions of the gene for pRB often\\nlead to development of an eye cancer\\n—\\nretinoblastoma —in childr en; later in life\\nthe mutations account for a gr eatly in -\\ncreased risk of osteosar comas (bone can -\\ncers). Mutant inherited versions of thep53 tumor suppr essor gene yield tumors\\nat multiple sites, a condition known asthe Li-Fraumeni syndr ome (named in\\npart for Fr ederick Li, co-author of\\n“What Causes Cancer?”, page 80).And the r ecently isolated BRCA1 and\\nBRCA2 genes seem to account for the\\nbulk of familial br east cancers, encom -\\npassing as many as 20 per cent of all pr e-\\nmenopausal breast cancers in this coun -\\ntry and a substantial pr oportion of fa -\\nmilial ovarian cancers as well. \\nEarly onset of tumors is sometimes\\nexplained by inheritance of mutationsin another class of genes as well.   As Iimplied earlie r, most people avoid can -\\ncer until late in life or indeﬁnitely be -\\ncause they enter the world with pristinegenes. During the course of a lifetime,howeve r, our genes ar e attacked by car -\\ncinogens impor ted into our bodies fr om\\nthe envir onment and also by chemicals\\nproduced in our own cells. And genetic\\nerrors may be intr oduced when the en -\\nzymes that r eplicate DNA during cell\\ncycling make copying mistakes. For themost par t, such er rors ar e rapidly cor -\\nrected by a r epair system that operates\\nin ever y cell. Should the r epair system\\nslip up and fail to erase an er ror, the\\ndamage will become a per manent mu -\\ntation in one of the cell’ s genes and in\\nthat same gene in all descendant cells.\\nThe system’ s high r epair efﬁciency is\\none r eason many decades can pass be -\\nfore all the mutations needed for a ma -\\nHow Cancer Arises Scientific American September 1996      69\\n16 17 18\\n16 17 18\\nCopyright 1996 Scientific American, Inc.', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 7}),\n",
       " Document(page_content='lignancy to develop will, by chance,\\ncome together within a single cell. Cer -\\ntain inherited defects, though, can ac -\\ncelerate tumor development thr ough a\\nparticularly insidious means: they im -\\npair the operation of pr oteins that r e-\\npair damaged DNA. As a r esult, muta -\\ntions that would nor mally accumulate\\nslowly will appear with alar ming fr e-\\nquency thr oughout the DNA of cells.\\nAmong the af fected genes ar e inevitably\\nthose contr olling cell pr oliferation. \\nSuch is the case in another inherited\\ncolon cancer , hereditar y nonpolyposis\\ncolon cancer . Afﬂicted individuals make\\ndefective versions of a pr otein r esponsi -\\nble for r epairing the copying mistakes\\nmade by the DNA r eplication appara -\\ntus. Because of this impair ment, colonic\\ncells cannot ﬁx DNA damage efﬁciently;they ther efore collect mutations rapidly ,\\naccelerating cancer development by twodecades or mor e. People af fected by an -\\nother familial cancer syndr ome, xer o-\\nderma pigmentosum, have inherited a\\ndefective copy of a gene that dir ects the\\nrepair of DNA damaged by ultraviolet\\nrays. These patients ar e prone to sever -\\nal types of sunlight-induced skin cancer .\\nSimilarly , cells of people bor n with a\\ndefective ATMgene have difﬁculty r ec-\\nognizing the pr esence of cer tain lesions\\nin the DNA and mobilizing the appr o-\\npriate r epair r esponse. These people ar e\\nsusceptible to neur ological degeneration,\\nblood vessel malfor mation and a variety\\nof tumors. Some r esear chers have pr o-\\nposed that as many as 10 per cent of in -\\nherited br east cancers may arise in pa -\\ntients with a defective copy of this gene.\\nOver the next decade, the list of can -\\ncer susceptibility genes will gr ow dra -\\nmatically , one of the fr uits of the Human\\nGenome Pr oject (which seeks to identify\\nevery gene in the human cell). T ogether\\nwith the incr easingly power ful tools of\\nDNA analysis, knowledge of these geneswill enable us to pr edict which members\\nof cancer -prone families ar e at high risk\\nand which have, thr ough good for tune,\\ninherited intact copies of these genes.\\nBeyond Pr oliferation\\nAlthough we have lear ned an enor -\\nmous amount about the genetic\\nbasis of r unaway cell pr oliferation, we\\nstill know rather little about the mutantgenes that contribute to later stages oftumor development, speciﬁcally thosethat allow tumor cells to attract bloodvessels for nourishment, to invade nearbytissues and to metastasize. But r esear ch\\nin these ar eas is moving rapidly . (Judah\\nFolkman describes the ingenuity of tu -\\nmor cells in generating their own bloodsupply in “Fighting  Cancer by Attack -\\ning Its Blood Supply ,” on page 150.\\nErkki Ruoslahti takes up metastasis in“How Cancer Spr eads” on page 72.)\\nWe are within striking distance of\\nwriting the detailed life histories of manyhuman tumors fr om star t to life-thr eat-\\nening ﬁnish. These biographies will bewritten in the language of genes andmolecules. W ithin a decade, we will\\nknow with extraor dinar y precision the\\nsuccession of events that constitute thecomplex evolution of nor mal cells into\\nhighly malignant, invasive derivatives. \\nBy then, we may come to understand\\nwhy cer tain localized masses never pr o-\\ngress beyond their benign, noninvasive\\nform to confr ont us with aggr essive ma -\\nlignancy. Such benign gr owths can be\\nfound in almost ever y organ of the body .\\nPerhaps we will also discer n why cer tain\\nmutant genes contribute to the for mation\\nof some types of cancer but not others.For example, mutant versions of the RB\\ntumor suppr essor gene appear often in\\nretinoblastoma, bladder car cinoma and\\nsmall cell lung car cinoma but ar e seen\\nonly occasionally in br east and colon car -cinomas. V ery likely , many of the solu -\\ntions to these mysteries will ﬂow fr om\\nresearch in developmental biology (em -\\nbryology). After all, the genes that gov -\\nern embr yonic development ar e, much\\nlater, the sour ces of our malignancies.\\nBy any measur e, the amount of infor -\\nmation gather ed over the past two de -', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 8}),\n",
       " Document(page_content='ern embr yonic development ar e, much\\nlater, the sour ces of our malignancies.\\nBy any measur e, the amount of infor -\\nmation gather ed over the past two de -\\ncades about the origins of cancer is with -\\nout parallel in the histor y of biomedical\\nresear ch. Some of this knowledge has\\nalready been put to good use, to build\\nmolecular tools for detecting and deter -\\nmining the aggr essiveness of cer tain types\\nof cance r, as David Sidransky discusses\\nin “Advances in Cancer Detection,” onpage 104. Still, despite so much insightinto cause, new curative therapies haveso far r emained elusive. One r eason is\\nthat tumor cells dif fer only minimally\\nfrom healthy ones; a minute fraction of\\nthe tens of thousands of genes in a cellsuffers damage during malignant trans-\\nformation. Thus, nor mal friend and\\nmalignant foe ar e woven of ver y similar\\ncloth, and any ﬁr e directed against the\\nenemy may do as much damage to nor -\\nmal tissue as to the intended tar get.\\nYet the course of the battle is chang -\\ning. The dif ferences between nor mal and\\ncancer cells may be subtle, but they ar e\\nreal. And the unique characteristics of\\ntumors pr ovide excellent tar gets for in -\\ntervention by newly developed dr ugs\\n[see the section “Therapies of the Fu -\\nture,” beginning on page 135]. The de -\\nvelopment of tar geted anticancer thera -\\npeutics is still in its infancy . This enter -\\nprise will soon move fr om hit-or -miss,\\nserendipitous discover yto rational de -\\nsign and accurate tar geting. I suspect\\nthat the ﬁrst decade of the new centur y\\nwill r eward us with cancer therapies\\nthat earlier generations could not havedreamed possible. Then this nation’ s\\nlong investment in basic cancer r esearch\\nwill begin to pay of f handsomely .\\nHow Cancer Arises 70 Scientific American September 1996The Aut hor\\nROBER T A. WEINBERG is Member of the Whitehead Insti -\\ntute for Biomedical Resear ch and a pr ofessor of biology at the\\nMassachusetts Institute of T echnology , wher e he ear ned his doc -\\ntoral degr ee in biology in 1969. His laborator y was instr umen -\\ntal in isolating the ﬁrst human oncogene and the ﬁrst human tu -\\nmor suppr essor gene. W einber g, a member of the National Acad -\\nemyof Sciences, has won many awar ds for his contributions to\\nthe understanding of cancer genetics, most r ecently the G.H.A.\\nClowes Memorial A ward of the American Association for Can -\\ncer Resear ch. This is his four th article for Scientiﬁc American.Further Reading\\nCancer: Science and Society . J. Cair ns. W . H. Fr eeman, 1978.\\nGenes and the Biology of C ancer. H. Varmus and R. A. W ein-\\nberg. Scientific American Librar y (distributed by W . H. Fr eeman),\\n1993.\\nThe Mul tistep N ature of C ancer. B. Vogelstein and K. W . Kinzler\\nin Trends in Genetics, Vol. 9, No. 4, pages 138–141; April 1993.\\nCancer: T he Rise of the Genetic P aradigm. J. M. Bishop in Genes\\nand Development, Vol. 9, No. 11, pages 1309–1315; June 1, 1995.\\nOncogenes. Second edition. G. M. Cooper . Jones and Bar tlett Pub -\\nlishers, Boston, 1995.Fund ament al Under standings\\nSA\\nCopyright 1996 Scientific American, Inc.', metadata={'source': 'Dataset/Weinberg-tumor progression.pdf', 'page': 8})]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Split text\n",
    "text = RecursiveCharacterTextSplitter().split_documents(documents)\n",
    "text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create a vectorstore\n",
    "vectorstore = FAISS.from_documents(text, embeddings)\n",
    "\n",
    "# Save the documents and embeddings\n",
    "vectorstore.save_local(\"vectorstore.db\")\n",
    "\n",
    "# create retriever\n",
    "retriever = vectorstore.as_retriever()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "# create document chain\n",
    "template = \"\"\"\"\n",
    "You are an assistant for question-answering tasks.\n",
    "Use the provided context only to answer the following question:\n",
    "\n",
    "<context>\n",
    "{context}\n",
    "</context>\n",
    "\n",
    "Question: {input}\n",
    "\"\"\"\n",
    "prompt = ChatPromptTemplate.from_template(template)\n",
    "doc_chain = create_stuff_documents_chain(llm, prompt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "chain = create_retrieval_chain(retriever, doc_chain)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question: What are the molecular mechanisms behind cancer development as discussed in Robert A. Weinberg's paper?\n",
      "Answer: The molecular mechanisms behind cancer development as discussed in Robert A. Weinberg's paper involve mutations in specific classes of genes, such as proto-oncogenes and tumor suppressor genes. Proto-oncogenes, when mutated, can become oncogenes that drive excessive cell proliferation. On the other hand, tumor suppressor genes contribute to cancer when they are inactivated by mutations, leading to uncontrolled cell growth. These mutations accumulate in the DNA of cells, ultimately leading to the development of malignancies. Additionally, abnormal signaling pathways within cells, caused by mutations in genes like ras, play a role in promoting cancer development.\n",
      "\n",
      "\n",
      "Question: How does the paper describe the role of oncogenes in the development of cancer?\n",
      "Answer: The paper describes how oncogenes drive excessive cell proliferation in cancer by mutating and becoming cancer-causing oncogenes that stimulate cell growth. Mutations in proto-oncogenes can lead to the production of too much growth-stimulating protein or an overly active form of it, causing uncontrolled cell proliferation. Conversely, tumor suppressor genes, when inactivated by mutations, contribute to cancer by removing crucial brakes that prevent inappropriate cell growth. The accumulation of mutations in half a dozen or more growth-controlling genes is necessary for a cancerous tumor to develop. Mutated genes can enable a proliferating cell to become invasive or capable of spreading throughout the body, leading to the formation of malignant tumors.\n",
      "\n",
      "\n",
      "Question: What insights does Weinberg provide about tumor suppressor genes and their function?\n",
      "Answer: Weinberg provides insights about tumor suppressor genes and their function by explaining how mutations in these genes can lead to cancer. Tumor suppressor genes code for proteins that inhibit cell division, and when these proteins are inactivated by mutations, cells lose crucial brakes that prevent inappropriate growth. He also mentions that introducing a tumor suppressor gene into cancer cells that lack it can restore a degree of normalcy to the cells, suggesting a potential way to combat cancer. Additionally, he discusses the importance of tumor suppressor genes in blocking the flow of signals through growth-stimulatory circuits and how their absence or inactivation in cancer cells can contribute to unchecked proliferation.\n",
      "\n",
      "\n",
      "Question: According to the paper, how do mutations contribute to the onset of cancer?\n",
      "Answer: Mutations in specific classes of genes within a cell can lead to the malignant transformation of the cell, allowing it to violate normal controls on proliferation and follow its own agenda for reproduction. These mutations accumulate over time and play a major role in triggering cancer by disrupting the normal processes of cell growth and division.\n",
      "\n",
      "\n",
      "Question: What new therapies for cancer treatment are suggested by Robert A. Weinberg?\n",
      "Answer: Robert A. Weinberg suggests that new therapies for cancer treatment could involve targeted anticancer therapeutics that focus on the unique characteristics of tumors, such as shutting down aberrantly firing growth factor receptors and developing compounds to block the synthesis of aberrant Ras proteins. These targeted therapies aim to intervene at the molecular level and could potentially revolutionize cancer treatment by moving towards rational design and accurate targeting of cancer cells.\n",
      "\n",
      "\n",
      "Question: What are the effects of climate change on polar bear populations?\n",
      "Answer: I'm sorry, but the provided context does not mention anything about the effects of climate change on polar bear populations.\n",
      "\n",
      "\n",
      "Question: How does quantum computing differ from classical computing?\n",
      "Answer: Quantum computing differs from classical computing in that it utilizes quantum bits (qubits) which can exist in multiple states simultaneously, thanks to the principles of superposition and entanglement. This allows quantum computers to perform complex calculations much faster than classical computers, especially for certain types of problems like factoring large numbers or simulating quantum systems.\n",
      "\n",
      "\n",
      "Question: What are the main causes of the global financial crisis of 2008?\n",
      "Answer: The context provided does not contain information about the main causes of the global financial crisis of 2008.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "questions = [\n",
    "    \"What are the molecular mechanisms behind cancer development as discussed in Robert A. Weinberg's paper?\",\n",
    "    \"How does the paper describe the role of oncogenes in the development of cancer?\",\n",
    "    \"What insights does Weinberg provide about tumor suppressor genes and their function?\",\n",
    "    \"According to the paper, how do mutations contribute to the onset of cancer?\",\n",
    "    \"What new therapies for cancer treatment are suggested by Robert A. Weinberg?\",\n",
    "    \"What are the effects of climate change on polar bear populations?\",  # irrelevant question\n",
    "    \"How does quantum computing differ from classical computing?\",  # irrelevant question\n",
    "    \"What are the main causes of the global financial crisis of 2008?\",  # irrelevant question\n",
    "]\n",
    "\n",
    "for question in questions:\n",
    "    response = chain.invoke({\"input\": question})\n",
    "    if response[\"answer\"]:\n",
    "        print(f\"Question: {question}\\nAnswer: {response['answer']}\\n\\n\")\n",
    "    else:\n",
    "        print(f\"Question: {question}\\nNo information\\n\\n\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "mlp",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.18"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
